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Development of Manganese-Enhanced Magnetic Resonance Imaging
(MEMRI) Methods to Study Pathophysiology Underlying
Neurodegenerative Diseases in Murine Models
Aditya N. Bade, Ph.D.
University of Nebraska Medical Center, 2015
Supervisor: Yutong Liu, Ph.D.
Manganese-enhanced magnetic resonance imaging (MEMRI) opens the great opportunity
to study complex paradigms of central nervous system (CNS) in freely behaving animals
and reveals new pathophysiological information that might be otherwise difficult to gain.
Due to advantageous chemical and biological properties of manganese (Mn2+), MEMRI
has been successfully applied in the studies of several neurological diseases using
translational animal models to assess comprehensive information about neuronal activity,
morphology, neuronal tracts, and rate of axonal transport. Although previous studies
highlight the potential of MEMRI for brain imaging, the limitations concerning the use of
Mn2+ in living animals and applications of MEMRI in neuroscience research are in their
infancy. Therefore, development of MEMRI methods for experimental studies remains
essential for diagnostic findings, development of therapeutic as well as pharmacological
intervention strategies.
Our lab has been dedicating to develop novel MEMRI methods to study the
pathophysiology underlying neurodegenerative diseases in murine models. In the first
study, we investigated the cellular mechanism of MEMRI signal change during
neuroinflammation in mice. The roles of neural cells (glia and neurons) in MEMRI signal
enhancement were delineated, and ability of MEMRI to detect glial (astrocyte and
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microglia) and neuronal activation was demonstrated in mice treated with inflammatory
inducing agents. In vitro work demonstrated that cytokine-induced glial activation
facilitates neuronal uptake of Mn2+, and that glial Mn2+ content was not associated with
glial activation. The in vivo work confirmed that MEMRI signal enhancement in the CNS
is induced by astrocytic activation by stimulating neuronal Mn2+ uptake. In conclusion,
our results supported the notion that MEMRI reflects neuronal excitotoxicity and
impairment that can occur through a range of insults that include neuroinflammation.
In the second study, we evaluated the efficacy of MEMRI in diagnosing the
complexities of neuropathology in an ananimal model of a neurodegenerative disease,
neuroAIDS. This study demonstrated that MEMRI reflects brain region specific HIV-1induced neuropathology in virus-infected NOD/scid-IL-2Rγcnull humanized mice. Altered
MEMRI signal intensity was observed in affected brain regions. These included, but were
not limited to, the hippocampus, amygdala, thalamus, globus pallidus, caudoputamen,
substantia nigra and cerebellum. MEMRI signal was coordinated with levels of HIV-1
infection, neuroinflammation (astro- and micro- gliosis), and neuronal injury.
Following the application of MEMRI to assess HIV-1 induced neuropathology in
immune deficient mice humanized with lymphoid progenitor cells, our successful
collaboration with Dr. Sajja BR (Department of Radiology, UNMC, Omaha, NE) led to
the generation of a MEMRI-based NOD/scid-IL-2Rγcnull (NSG) mouse brain atlas. Mouse
brain MRI atlases allow longitudinal quantitative analyses of neuroanatomical volumes
and imaging metrics. As NSG mice allow human cell transplantation to study human
disease, these animals are used to assess brain morphology. MEMRI provided sufficient
contrast permitting 41 brain structures to be manually labeled on average brain of 19
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mice using alignment algorithm. The developed atlas is now made available to
researchers through Neuroimaging Informatics Tools and Resources Clearinghouse
(NITRC) website (https://www.nitrc.org/projects/memribrainatlas/).
Finally, we evaluated the efficacy of N-acetylated-para-aminosalicylic acid
(AcPAS) to accelerate Mn2+ elimination from rodent brain, enabling repeated use of
MEMRI to follow the CNS longitudinally in weeks or months as well as inhibiting the
confounding effects of residual Mn2+ from preceding administrations on imaging results.
Two-week treatment with AcPAS (200 mg/kg/dose × 3 daily) accelerated the decline of
Mn2+ induced enhancement in MRI. This study demonstrated that AcPAS could enhance
MEMRI utility in evaluating brain biology in small animals.
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CHAPTER – 1
Manganese (Mn2+) -Enhanced Magnetic Resonance Imaging
(MEMRI)
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1.1. Introduction
As being an excellent non-invasive tool with high spatial resolution and outstanding
capacity for differentiating soft tissues to provide anatomical information of biological
systems, magnetic resonance imaging (MRI) has become a pillar of radiological
techniques in diagnostic imaging and has emerged as the major mode for assessing
central nervous system (CNS) disorders [1]. MRI was introduced three decades ago into
the clinical medicine [1]. Due to its properties, a variety of controls over image contrast,
great flexibility and specificity in the detection of different pathophysiological
mechanisms, metabolism assessment and anatomical as well as functional mapping, MRI
has achieved widespread success not only in clinical, but also in research field [1-3].
Over the last 10 years, MRI utilization in experimental science has augmented [2][4,5].
Specially designed MRI units for experimental animals are now commercially available.
Pictures of MRI units available for rodents at University of Nebraska Medical Center
(UNMC) bio-imaging core facility are shown in figure 1.1. MRI acquisition softwares as
well as post-processing tools are widely accessible [2]. Public and private financial
sources have reinforced the expansion of MRI based brain atlases and databases [2].
In neuroscience research, innovations in diagnostic and therapeutic fields
employing experimental animals rely on MRI. Availability of MRI in clinical as well as
preclinical settings permits direct linking of findings between humans and experimental
animals [3]. This non-invasive imaging tool has been used in the studies involving animal
models of several neurological diseases, such as stroke, Parkinson’s disease, Alzheimer’s
disease, and NeuroAIDS, epilepsy, brain tumors, multiple sclerosis, and other brain
disorders [1-3,6-8].
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Advances in MRI applications provide remarkable information about brain
morphology, metabolism, physiology and function. The desire of obtaining more detailed
information from brain, during normal and diseased conditions, with the help of MRI to
improve our understanding is becoming more prominent. Thus, the interest in the use of
contrast agents is increasing.

1.2. MRI contrast agents [1,9-13]
MRI uses hydrogen atoms of water molecules to generate images. The primary
contrast in MRI image mainly results from regional differences in intrinsic factors, T1 and
T2, spin-lattice and spin-spin, relaxation times. Proton density (PD), which is also termed
as spin density (SD) is another factor affecting image contrast. These factors are
independently chosen to generate the tissue image contrast. The differentiation between
healthy and diseased tissue depends upon their distinctive signal intensity that relies on
tissue PD, T1 and T2 relaxation times. However, the signal intensity generated by these
intrinsic contrast factors of healthy and diseased tissue frequently too limited to enable
sensitive and specific diagnosis. Intrinsic relaxation times of healthy and diseased tissues
frequently overlap, leading to compromised detection of abnormal tissue or function.
This limitation can be overcome by using MRI contrast agents.
Agents that affect the MRI signal contrast are paramagnetic (e.g. Mn2+, Gd), and
superparamagnetic (e.g. iron oxide particles, such as Fe2O3, Fe3O4) and ferromagnetic
(e.g. albumin coated magnetite). These agents help to increase sensitivity and specificity
of MRI signal acquisition and provide substantial diagnostic information by reducing T1
and T2 relaxation times of surrounding water protons in targeted tissue, leading to
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generation of signal enhancement in shorter period of time and better signal-to-noise
ratio.
In biomedical research, most widely used contrast agents are paramagnetic and
superparamagnetic. Depending upon the characteristics, such as chemical composition,
molecular size, in vivo distribution, pharmacokinetic properties, and individual’s research
question, agents are chosen for different studies. In our lab, we have used paramagnetic
agent, Mn2+, to study neurodegenerative diseases that are modeled using rodents, due to
its advantageous chemical and biological properties.

1.3. Paramagnetic contrast agents
Lauterbur et al. first suggested the use of paramagnetic ions as contrast agent for MRI in
1978 [14]. Paramagnetic agents possess a permanent magnetic moment, which are
randomly aligned in the absence of an externally applied magnetic field. When
paramagnetic material senses externally applied magnetic field, the respective magnetic
moments align parallel to the applied field. Furthermore, aligned magnetic moments
generate a local magnetic field, leading to an effective reduction in T1 (spin-lattice) and
T2 (spin-spin), relaxation times of surrounding water protons of the targeted organ
systems. Reduction in the relaxation times results in MRI signal changes [1,9,10,12].
Paramagnetic property of the material is based on the presence of number of
unpaired electrons in atom. Most known subgroups of paramagnetic compounds are
metal ions (e.g. Mn2+) and lanthanide elements (e.g. gadolinium (Gd)). The magnetic
moment of unpaired electrons is greater than that of unpaired neutrons or protons.
Therefore, agents with unpaired electrons are exclusively apt as MRI contrast agent
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[9,10,12]. Even though, paramagnetic agents affect both T1 and T2 relaxation times, the
shortening of T1 mainly causes an increase in signal intensity. The result of increase in
signal intensity remains until the concentration of agent is reached to optimal level. Thus,
use of paramagnetic material as a MRI contrast agent is advantageous, as it exhibits
greater effects on T1 than on T2 relaxation time.

1.4. Mn2+ – a paramagnetic contrast agent
Mn2+, divalent ion, has paramagnetic properties. It has 5 unpaired electrons and causes
strong reduction of both T1 and T2 relaxation times of surrounding water protons of
targeted tissue [6,13,15,16]. The magnitude of T1 or T2 relaxation time reduction depends
on the local Mn2+ concentration. It can be described by following equation [13]:
Rio = Rt(0) + Ri [Mn2+]
Where,
Rio = 1/Ti (i=1,2) is the observed relaxation rate
[Mn2+] = the concentration of the Mn2+ ion
Ri = the relaxivity constant, and
Rt(0) = the relaxation rate of the solvent without manganese ([Mn2+] = 0)
The use of Mn2+, a divalent ion, and its unique properties as a MRI contrast agent is
known as Mn2+-enhanced magnetic resonance imaging (MEMRI).

1.5. MEMRI
The investigation of Mn2+ as contrast agent coincides with early days of nuclear magnetic
resonance (NMR) [4,6,17]. Initial findings with the help of Mn2+ played important role in
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understanding of water-exchange effects, which was a crucial step in the development of
T1 shortening contrast agents [4,6,18,19], and quantitative structural information of
biological systems, which helped to develop techniques to confirm three-dimensional
protein structure using NMR [4,20]. Mn2+ has been present since the beginning of MRI.
Lauterbur et al. with the help of Mn2+ showed that relaxation times could affect signal
intensity. Over 25 years ago, the use of Mn2+ as a MRI contrast agent was initialized.
London et al. studied toxic effects of Mn2+ on anesthetized rats [21]. Since then, the use
of MEMRI in experimental neuroscience for imaging the rodent brain has significantly
evolved [4]. Our observation about MEMRI use in neuroscience research over the last 10
years is showed in figure 1.2.a and 1.2.b. Paramagnetic property of Mn2+ causes an
effective reduction of the T1 (spin-lattice) relaxation times of the surrounding water
protons of the targeted organs, leading to signal enhancement. Positive contrast signal
enhancement is detected on T1-weighted images of tissues in which Mn2+ accumulates
[4,6,9,12,15,16,22]. The difference between 3-D MRI image of brain of a mouse which
was injected with MnCl2 and 3-D MRI image of a brain of a mouse injected with saline
showed in figure 1.3. Mn2+-based contrast enhancement and neuroarchitecture details are
clearly visible in these mice. Yet, one major weakness of Mn2+ is associated cellular
toxicity upon overexposure [4-6,12,15,16,23]. However, Mn2+ is considered as least toxic
among the essential trace elements. This divalent ion is also an essential trace element, as
the lack of it leads to severe disorders in humans [5,6,16,24].
Interpretation of MEMRI findings requires profound knowledge of Mn2+ behavior
in biological systems under healthy and diseased conditions as well as of experimental
considerations. Therefore, following sections will introduce the properties of Mn2+ and its
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entrance in the CNS, main applications of MEMRI in biological systems, methodological
considerations of Mn2+administration in animals, Mn2+ toxicity, MEMRI in humans, and
objective and related study aims of my Ph.D. thesis.

1.6. Properties of Mn2+ in the CNS
Mn2+ is recognized by biological systems as a chemical analogue of calcium (Ca2+), same
charge and similar ionic radii (Mn2+ = 89 pm and Ca2+ = 114 pm) [6]. Therefore, Mn2+
can enter into the neurons and other excitable cells through voltage-gated calcium
channels (L-type voltage-gated Ca2+ channels), NMDA receptors, Na2+/ Ca2+ exchanger,
and Na2+/ Mg2+ antiporter [4-6,12,15,25-30]. Once inside the cells, it binds with high
affinity to proteins and nucleic acids. Inside the neuronal cells, Mn2+ accumulates in the
endoplasmic reticulum (ER), is packaged into the vesicles and is transported along the
axons anterogradely [5,6,25,27,31]. Upon reaching the pre-synaptic membranes it is
released at the synaptic cleft and taken up by the adjacent neurons [4-6,15,25,27].
Scheme of Mn2+ transport mechanism between neurons in CNS is depicted in figure 1.4.
Systemic administration of Mn2+ leads to its accumulation in all tissues,
significantly detected in liver, kidney, heart and brain [6,16,32,33]. As major route of
entry for Mn2+ into the CNS is through CSF-Blood barrier, the time course, uptake and
distribution of Mn2+ varies across the brain regions [6,15,16]. Initial Mn2+ accumulation
occurs in the brain regions near to ventricles and then gets distributed throughout the
entire brain. Contrast enhancement in CNS reaches to its equilibrium 24 hours after
MnCl2 administration (Figure 1.5) [6,15,16,32,34,35]. It has been shown that Mn2+ has
very slow clearance rate from the brain. It can take up to 300 days to clear from the brain
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tissue [16]. Mn2+ has long half-life in the brain, 51–74 days in rodents [16,36] and more
than 100 days [6,37] in monkeys, whereas short half-life in visceral organs like liver and
heart, which might indicate that Mn2+ is carrier-transported into the brain, but not out of it
[6,16,36]. Efflux of Mn2+ from brain is not well studied but is believed that the efflux
mechanism is diffusion mediated [6,38].

1.7. Entry of Mn2+ into the CNS
Mn2+ enters into the brain via the following three major routes [4-6,12,15,16].
After systemic administration of MnCl2, Mn2+ enters the brain through two different
routes as follows:
1) Through choroid plexus via CSF (major and rapid entry route)
2) Through BBB by diffusion or active transport processes (minor entry route)
At physiological plasma Mn2+ concentration, it is mainly transported across the
endothelial cells of brain capillaries, and after bolus systemic injection of Mn2+ (at high
concentration), the major route of entry is via choroid plexus.
Application of Mn2+ via the olfactory system provides the easiest route for Mn2+
entrance into the brain, as olfactory tract is not protected by the BBB or other barriers. It
has been shown in rodents that upon exposure to air containing Mn2+, it is able to enter
into the olfactory bulb via the olfactory epithelium.
3) Through olfactory nerve via olfactory epithelium

1.8. Mn2+ - an intracellular contrast agent
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Two essential factors have been derived from the results obtained with the help of Mn2+
[16,22].
1) Signal received after MnCl2 administration comes from the intracellular Mn2+,
whereas another popular paramagnetic MRI contrast agent, chelated
gadolinium, remains extracellular. Therefore, MEMRI has been useful to map
signal intensities according to cellular density of the targeted tissue, and thus to
visualize brain cytoarchitecture.
2) Rate of Mn2+ uptake is useful to detect normal and affected tissue functions.
Normal uptake defines the normal function of the tissue. Therefore, disruption
of Mn2+ uptake serves as a biomarker to detect the pathological conditions such
as stroke, neuroAIDS, epilepsy, etc.

1.9. Applications of MEMRI in experimental neuroscience
Depending upon above mentioned properties of Mn2+, literature has divided the
applications of MEMRI as a research tool in three major groups [5,6,15,16,22]. But, here,
I have divided the applications in four major groups.
1) Measurement of neuronal activity (functional assessment); this application of
MEMRI is termed as activation-induced MEMRI (AIM-MRI) [29]; figure 1.6
2) Assessment of anatomical/morphological details [6]; figure 1.3
3) Assessment of neuronal tracts and assessment of axonal connectivities [6]; figure
1.7
4) Assessment of rate of axonal transport [5]
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Taking advantage of these applications, researchers have been using MEMRI in
neurosciences to address problems using translational models of brain diseases.

1.10. Methodological considerations for Mn2+ administration
1.10.1 Preparation of MnCl2 solution:
The most common and easy way to deliver Mn2+ to the experimental animals is through
the injection of MnCl2 solution [6,15,16]. After administration, MnCl2 dissociates into
Mn2+ and Cl-. The salt material (MnCl2) is commercially available in three different
grades in major biochemical companies, for example:
1) MnCl2, powder form, anhydrous, purified (> 99%), molecular weight (M.W.)- 125.84
g/mol (Sigma-Aldrich, St Louis, MO)
2) MnCl2·4H2O, flake form, hydrous, highly purified (99.99%), M.W.- 197.91 g/mol
(Sigma-Aldrich, St Louis, MO)
3) MnCl2 solution, prepared in 18 megohm water, 1.00 ± 0.001 M (Sigma-Aldrich, St
Louis, MO)
All three forms are suitable for experimental purpose. We have used MnCl2·4H2O for all
the studies carried out in our laboratory and for studies mentioned in my dissertation.
Chemical and physical properties, especially osmolarity and pH, of the MnCl2
solution to be used for experimental purpose need to be considered for successful
application [6,15,16]. Osmolarity of body fluid is around 300 mOsm/l. One has to make
sure that administered amount of MnCl2 will not affect the natural osmolarity by using
the isotonic solution of MnCl2, 100 mM. Solutions with significant lower osmolarity
(<100mM) are hypotonic, and solutions with significant higher osmorality (>100 mM)
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are hypertonic. This parameter has strong impact when MnCl2 solution is injected
directly into the brain tissue (stereotaxic injection), but has very minor consequences
when

injected

systemically,

including

intravenous

(IV),

intraperitoneal

(IP),

subcutaneous (SC). For all of our studies, MnCl2 has been administered systemically,
especially through intraperitoneal route [25,39,40]. Therefore, we have been successfully
using the MnCl2 solution with lower concentration (50 mM).
Another important property to consider while preparing the MnCl2 solution is pH.
It is essential to adjust the pH of the solution at 7.4 for effective application. The
procedure used to prepare MnCl2 solution for our studies is described in materials and
methods section of respective chapters.

1.10.2. Administration of Mn2+
Due to acute and chronic cellular toxicity of Mn2+, one has to take into consideration of
experimental methodology, including delivery route, appropriate dose, osmolarity as well
as pH of MnCl2 solution to deliver adequate amount of Mn2+ to the site of interest in a
time efficient manner to receive desired contrast signal while avoiding any toxic effects
of Mn2+ to experimental animals and its interference with normal physiological
properties.
It has been showed that systemic administration of MnCl2 solution in a
fractionated manner (i.e. smaller doses, multiple injections) is beneficial to reach
sufficient Mn2+ accumulation into tissues (especially brain) to obtain high contrast signal
while minimizing toxic side effects [23,41]. We used fractionated administration scheme
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for all of our studies [25,39,40]. Below, I have summarized commonly used
administration routes for MnCl2 solution in the literature.
In order to increase the efficiency of MEMRI, the delivery route is chosen based
on the application [4,5,13,15,16]. MEMRI applications are described under the heading
applications of MEMRI in experimental neuroscience in the current chapter. In general,
MnCl2 can be injected intraperitoneally (IP), intravenously (IV), subcutaneously (SC),
intracranially (stereotaxic injection) into the area of interest, and can be delivered by
using commercially available osmotic pumps. Among systemic administration routes (IP,
SC, IV), there is no strong evidence suggesting that one route is better than others or that
one route causes lesser toxicity compared to others.
Kuo et al. measured relative T1 relaxation times in mice (C57Bl/6) brains with
different modes of systemic administration (IP, IV, SC). Authors concluded that all the
systemic routes of administration showed significant reduction in T1 values following
MnCl2 infusion and both the temporal and regional changes in cerebral T1 relaxation
times are relatively independent of the route of administration [42].
Few studies have used osmotic pumps to deliver Mn2+ into the experimental
animals [13,43,44]. Osmotic pumps deliver a specific concentration of Mn2+ over a
specified period of time. It has been proposed that slow release of Mn2+ can decrease
associated toxicity issues. Currently, ALZET® osmotic pumps company (Durect
Corporation, CA) sales pumps in the market. Company describes that ALZET pumps
operate on osmotic pressure difference between the tissue environment (in which the
pump is implanted) and a compartment within the pump. When water enters into the
pump compartment from the surrounding tissue, it compresses the flexible reservoir,

13
leading to displace MnCl2 solution from the reservoir at a controlled rate to the
surrounding body environment of the animal. ALZET provides a variety of delivery rates,
SC or IP.

1.11. Mn2+ - a trace element and related toxicity
Mn2+ is an essential heavy metal for cellular processes and normal development. It plays
essential role in the regulation of metabolism, cell energy, immune response, blood sugar
homeostasis, blood clotting, reproduction, digestion, skeletal system development, bone
growth as well as in synaptic function as an antioxidant and enzymatic cofactor in the
brain [5,6,45,46]. It serves as a significant co-factor for enzymes such as glutamine
synthetase, pyruvate carboxylase, arginase, phosphoenolpyruvate carboxykinase and
mitochondrial superoxide dismutase [5,6,46,47]. In humans, deficiencies in Mn2+ are
associated with skin lesions, epileptic seizures, bone malformation, increased Ca2+ and
phosphorous levels, among others [5,16]. Mn2+ is generally excreted through the
hepatobiliary route [6,47,48]. However, in excess, Mn2+ is toxic [4-6,15,16,47]. Acute
overexposure to this ion happens when administered systemically to patients, leading to
cardiac toxicity, renal failure, liver toxicity, and may be death [6,16]. Moreover, chronic
exposure to Mn2+ is neurotoxic, a brain disorder characterized by neurological and
psychological

disorders,

a

progressive

neurodegenerative

disorder,

called

as

‘Manganism’, accompanied by loss of Dopaminergic neurons [5,16]. In this disorder,
Mn2+ is highly concentrated in basal ganglia. Symptoms of manganism are similar to
symptoms of Parkinson’s disease, such as tremors, widespread rigidity, hallucination,
bradykinesia, sleep disorder, lack of facial expressions, slurred speech and memory loss
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[15,49]. It was observed that excessive exposure of this heavy metal damages the CNS by
a

number

of

mechanisms,

including

inhibition

of

mitochondrial

oxidative

phosphorylation, which leads to reduced ATP [49,50], impaired astrocyte-neuronal
interactions, indirect effect on excitatory and inhibitory influences [47]. Aberrant Mn2+
accumulation in brain has also been linked to Huntington’s disease and other neurological
disorders [49]. Normal human brain Mn2+ concentration is at 5.32-14.03 ng Mn2+/mg
protein, which is equivalent to 20-52.8 µM Mn2+ (around 1.1-2.9 ppm). General toxic
responses occur when Mn2+ concentration is elevated to around 3 fold (i.e. 15.96-42.09
ng Mn2+/mg protein or 60.1-158.4 µM Mn2+) [49].
The most common method to administer Mn2+ to experimental animals is through
the injection of MnCl2 solution. Detailed information about MnCl2 solution and
administration routes are discussed under the heading preparation of MnCl2 solution and
administration on Mn2+ in the current chapter. This paragraph discusses toxicity related to
MnCl2. According to the Material Safety Data Sheet (MSDS) [16], MnCl2 is a harmful
chemical agent, which causes eye and skin irritation upon contact. Target organs include
the CNS and the lungs. As per the MSMDS report, following characteristic signs and
symptoms of exposure have been identified: ‘Men exposed to manganese dusts showed a
decrease in fertility. Chronic exposure primarily affects CNS, and early symptoms are
languor, sleepiness and weakness in the legs.’ In more advanced cases, emotional
disturbances such as uncontrollable laughter and a spastic gait with tendency to fall while
walking. Mn2+ is also known to be a potential mutagen, and pneumonia is highly
observed in the workers exposed to dust of Mn2+ compounds. Therefore, one must wear
appropriate barriers and take proper precautions while interacting with MnCl2 material
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for experimental purposes. LD50 toxicity data reports in the MSDS for MnCl2 are shown
in Table 1 [16].
Indeed, acute and chronic cellular toxicity of Mn2+ repressed its transformation as
clinical MRI contrast agent. Regardless of these toxicity issues, to take the advantage of
chemical and biological properties of Mn2+ as a contrast agent, researchers generated
alternative ways to avoid toxicity of Mn2+ while delivering sufficient amount of Mn2+ to
the site of interest in an efficient manner in experimental animals.
For all of our studies, level of Mn2+ used is below the neurotoxic levels. Animals
were observed daily after each i.p. MnCl2 injection and 24 hours after the injection to
detect Mn2+ toxicity. If tremor or convulsion (signs of Mn2+ overdose) persisted longer
than 3 minutes or lethargy (decreased locomotion), and loss in body weight was observed
at 24 hours, mice were euthanized [25]. Moreover, it is demonstrated that concentration
of Mn2+ > 200 µM can affect the neuronal activity [51]. We measured the R1 values to
determine absolute Mn2+ concentration before and after Mn2+ administration in cortex
region of mice (n=11). There was ~ Δ 0.15 alteration in R1 values after Mn2+
administration. R1 values were less than 0.70 after Mn2+ administration (Figure 1.8).
These R1 values then were compared with previously reported correlation between R1
values and relative Mn2+ concentration. This comparison corresponded to less than 40
µM Mn2+ in the brain parenchyma region of experimental animal used in our studies
(Figure 1.8). Thus, with the help of behavioral observation and measured R1 values, we
confirmed that our fractionated administration scheme for MnCl2 is non-toxic to animals
and injected Mn2+ does not have effect on neuronal activity.
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1.12. MEMRI in Humans
Even though the use of Mn2+ as a MRI contrast agent in clinical settings has been
restricted due to cellular toxicity, properties of Mn2+ such as high sensitivity and
specificity, and its prominent results in rodent, song birds, and monkeys, encouraged
researchers to develop chelates of Mn2+ for the clinical use. Several chelates were
developed and few of them were introduced into the market by biochemical companies.
Manganese dipyridoxaldiphosphate (MnDPDP) was the first Mn2+-based contrast agent
approved by FDA. This product was approved for the liver imaging [5,6,9,16,52,53].
Product containing Manganese dipyridoxaldiphosphate (MnDPDP) was introduced into
the market by GE healthcare called Teslascan®. MnDPDP is anionic chelate and
dissociates quickly after administration to yield free Mn2+ ions. Although MnDPDP was
mainly considered for liver imaging, some studies demonstrated its usefulness in imaging
of pancreas and biliary tract [9]. Another pharma-company, Eagle Vision Pharmaceutical,
is testing contrast agent called SeeMore® for cardiac imaging [5]. This product consists
free Mn2+ ions formulated along with Ca2+ ions to outweigh the transient effect of Mn2+
as a Ca2+ inhibitor. This agent is currently used in dogs and pigs for cardiac and vascular
imaging. Few promising chelating agents were invented for clinical use, however, further
research needed for successful translation of MEMRI.
MEMRI has been successfully used in previous studies to study brain disorders in
experimental animals. Although previous studies highlight the potential of MEMRI for
brain imaging, the limitations and boundaries concerning the use of Mn2+ in living
animals and development of new MEMRI applications in neuroscience are at the
beginning level. Therefore, during the course of my Ph.D, we have determined the
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cellular source for altered signal intensity during pathological conditions, evaluated the
efficacy of chemical compound for washing out the Mn2+ from the rodent brain for
longitudinal studies, and developed tools such as 3-D mouse brain atlas, which is now
available for public use at NIRTC resources.

1.13. Objective and aims of the thesis
1.13.1. Objective
To develop manganese-enhanced magnetic resonance imaging (MEMRI) methods to
study pathophysiology underlying neurodegenerative diseases in murine models.

1.13.2. Aims
1) Investigate role of glia and neurons in manganese-enhanced magnetic resonance
imaging (MEMRI) signal enhancement during inflammation (Chapter 2).

2) Evaluate the application of MEMRI in diagnosing the brain pathology in animal
models of neurodegenerative diseases (Chapter 3).

3) Generate MEMRI-based NOD/scid-IL-2Rγcnull mouse brain atlas (Chapter 4).

4) Evaluate the efficacy of N-acetylated-para-aminosalicylic acid (AcPAS) to accelerate
Mn2+ elimination from rodent brain (Chapter 5).
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Figure 1.1. MRI units for small animals at UNMC bio-imaging core facility. Both
scanners are 7 Tesla/21 cm, Bruker Biospin (Bruker, Billerica, MA)
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(a)

(b)

Figure 1.2. MEMRI in experimental neuroscience. Distribution of MEMRI publications
in (a) years and (b) neuroscience-related topics
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Figure 1.3. Three-dimensional MRI image of mouse brain with and without Mn2+.
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Figure 1.4. Scheme of Mn2+ transport mechanism in CNS. (a) Once Mn2+ entered the
CNS, it enters the neurons through voltage gated Ca2+ channels. (b) Inside neurons, ions
are accumulated in the endoplasmic reticulum and packaged into vesicles. (c) Mn2+ ions
are further transported anterogradely along the axons with the help of microtubule
assembly. (d and e) Upon reaching to the presynaptic terminal, Mn2+ ions get released at
the synaptic cleft (f) and taken up by the adjacent neuron. Figure is modified from [12]

22

Figure 1.5. Temporal Mn2+ distribution across the brain. (Top) Coronal, (middle) sagittal
and (bottom) axial MEMRI sections of a mouse brain in vivo 2, 8, and 24 h after
intraperitoneal injection of 320 μmol/kg MnCl2 (9.4 T, 100 μm isotropic resolution). Cb,
cerebellum; cp, choroid plexus; CSF, cerebrospinal fluid; dg, dental gyrus; fr, fasciculus
retroflexus; gp, globus pallidus; ha, habenula; ic, inferior colliculus; ipn, interpeduncular
nucleus; lh, lateral habenula; ls, lateral septum; ob, olfactory bulb; pi, pituitary gland; pv,
periventricular tissue; str, striatum; th, thalamus. Figure is adapted from [6]
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(a)

(b)

Figure 1.6. MEMRI measures neuronal activity. (a) MEMRI of acute cocaine-induced
brain activation. Activation maps are superimposed onto T2-weighted MRI with
corresponding rat brain atlas sections shown on the right. Activated voxels are clustered
in the hemisphere with the BBB disrupted by hyperosmolar mannitol. The contralateral
hemisphere had an intact BBB and did not show activation. Activated structures include
olfactory cortex; medial, ventral, and lateral orbital cortex; pre-limbic cortex; cingulate
cortex; nucleus accumbens (NAc), caudate putamen; ventral pallidus; external globus
pallidus; agranular insular cortex; thalamus; hypothalamus; retrosplenial dysgranular
cortex; hippocampus; and primary and secondary somatosensory and motor cortex. (b)
Averaged MEMRI response time course in the NAc from animals receiving saline (n = 6)
and 0.5 mg/kg (n = 5) and 2.0 mg/kg (n = 6) cocaine. All time courses were normalized
to the baseline signal after bolus injection of mannitol, but before the injection of cocaine
or saline. Figure is adapted from [29]
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Figure 1.7. MEMRI detects neuronal tracts. (a, b) Horizontal and (c) axial MEMRI
sections and (d) 3D volume rendering of a mouse optical system in vivo 24 h after
intravitrial administration of 0.06 μmol MnCl2 (2.35 T, 117 μm isotropic resolution). lgn,
lateral geniculate nucleus; och, optic chiasm; on, optic nerve; ot, optic tract; sc, superior
colliculus. Figure is adapted from [6]
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(a)

(b)

Figure 1.8. Measurement of R1 values. (a) R1 (1/T1) values were measured in mice brain
cortex before and after Mn2+ injections. Mice were injected with our lab optimized
fractionated MnCl2 injections. (n=11). (b) R1 values plotted against MnCl2 concentration,
significant linear correlation was observed between the two (n = 4 MRI acquisitions, P <
0.0001, r: Pearson’s correlation coefficient). Panel b of the figure is adapted from [51]
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Table 1.1. LD50 (toxicity) data for MnCl2.

Table is adapted from [16].
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CHAPTER - 2
Role of Glia and Neurons in Manganese-Enhanced Magnetic
Resonance Imaging (MEMRI) Signal Enhancement During
Inflammation
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2.1. Introduction
Manganese (Mn2+) is a potent magnetic resonance imaging (MRI) contrast agent used to
improve anatomical visibility, most notably, neural structures. Unlike other agents, such
as gadolinium, iron oxide, iron platinum and protein-based compounds, Mn2+ remains at
a very early stage in clinical development, based in large measure to its inherent
neurotoxicity [1-3]. Nonetheless, a number of recent reports demonstrate that Mn2+enhanced MRI (MEMRI) in normal animal brains provide novel information relevant to
anatomical, integrative, and functional assessments of neuronal connectivity. These
findings are linked to the abilities of Mn2+ ions to efficiently enter neurons through
voltage-gated calcium channels [4-7].
A major drawback for the use of Mn2+ as a contrast agent in studies of human
disease models rests in understanding its cellular mechanism and profiles [8,9]. Despite
such potential limitations, significant attempts have been made, in recent years, to use
MEMRI in studies of the pathobiology of neurodegenerative diseases utilizing relevant
animal models [9-25]. Nonetheless and paramount to the successful

application of

MEMRI is not simply the ability to deliver Mn2+ to the site of interest or of disease but
in determining the cell types and cellular mechanisms that engage the ion and produce the
signal enhancement observed. Based on our long standing interest in the links between
neuroimmunity and neurodegenerative diseases we reasoned that pathological activation
of the immune-competent glial cells could represent an obligatory event for any MEMRI
signal enhancements. In support of this idea is a wealth of prior studies demonstrating
that MEMRI signal enhancements were co-localized with reactive glia [14,22,26,27].
Reproduced with permission from Bade AN, Zhou B, Epstein AA, Gorantla S, Poluektova LY, Luo J,
Gendelman HE, Boska MD, Liu Y; Improved Visualization of Neuronal Injury Following Glial Activation
by Manganese Enhanced MRI; J Neuroimmune Pharmacol. 2013, Sep; Copyright Springer
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However, it was never clear if such signal enhancements resulted from Mn2+
accumulation in the glial cells directly, or from elevated manganese uptake by neuronal
cells stimulated by glial reaction.
Thus, we sought to better elucidate the cellular basis of MEMRI signal in studies
of neurodegenerative diseases. We reasoned that if the cell association of the signal
enhancement is determined, MEMRI can be developed as a potential imaging tool to
monitor real-time glial-neuronal interactions. To this end, we investigated relationships
between microglial and astrocytic activation linked to Mn2+ uptake. These studies were
both in vitro as performed in glial and neuronal cells and in vivo using MRI following
lipopolysaccharide (LPS) treatments in mice. The results showed that astrocytic reactions
result in MEMRI signal enhancement by stimulating neuronal Mn2+ ion uptake.

2.2. Materials and Methods
2.2.1. PC-12 Differentiation
A rat adrenal pheochromocytoma-derived cell line - PC-12 Tet-Off, was used to study
neuronal Mn2+ uptake. PC-12 cells were utilized here because they serve as a relevant in
vitro model system for primary neuronal cells [28,29]. They have been widely used to
study voltage-gated Ca2+ channels [30,31] and effects of Mn2+ exposure on these cells
[2,32,33]. Following withdrawal of doxycycline (Dox) from the medium, PC-12 cells
were differentiated with nerve growth factor (NGF, R&D Systems 1156-NG/CF).
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2.2.3. Cell Co-culture and Activation

Figure 2.1. PC-12 cells (differentiated to neurons) were co-cultured with primary
astrocytes or microglia respectively at the cell ratio of 1:1 (105 cells).

Primary cultured mouse astrocytes and microglia were prepared from NOD-scid IL2Rgnull
(NSG) newborn pups as described in [34,35]. Differentiated PC-12 cells were de-attached
and seeded in multi-well plates. Primary astrocytes and microglia were placed on inserts
and co-cultured with PC-12 cells respectively at the cell ratio of 1:1 (105 cells, Fig. 2.1).
The co-cultured cells were then treated with a combination of cytokines including
interferon gamma (IFN-) and tumor necrosis factor alpha (TNF-) at the following
concentrations: 25 (IFN-) and 2.5 (TNF-), 50 and 5.0, or 100 and 10.0 ng/ml to induce
glial activation. After nine hours of treatment, MnCl2 solution was administered in the
medium at concentrations of 80, 160 and 320 M. An untreated cell group was used for
control measurements. Cells were washed and resuspended at 2 and 15 hours after MnCl 2
treatment. Inductively coupled plasma mass spectrometry (ICP/MS) was used to measure
the Mn2+ concentration. Experiments were performed with triplicate samples.
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2.2.4. Mouse Model of Acute Neuroinflammation
All animal procedures performed in this study were approved by the University of
Nebraska Medical Center Institutional Animal Care and Use Committee. LPS was
intracranially (i.c.) injected to induce focal inflammation in male wild-type C57BL/6
mice (n = 13, 6-8 weeks old). Using a stereotactic injection device, 10 µg (LPS) in 2 µl
PBS was administrated into the left hemispheric caudoputamen (coordinates from
bregma: 3.0 mm lateral, 0.5 mm anterior, and −3.5 mm ventral). The LPS solution was
delivered with a 27 g needle at the flow rate of 0.2 µl per minute. A sham-operated
control group (n = 11) was injected with 2 µl PBS through the i.c. route with the same
parameters as the LPS group.

2.2.5. MEMRI
MnCl2 (50 mM) was administrated i.p. with the dose of 60 mg/kg consecutively four
times at 24 hour intervals before MRI. Another group of mice (n = 10) with i.c. LPS
injection was added to study the effect of LPS alone on MRI signal enhancement. This
group was administrated with saline through the i.p. route with the volume of 6 ml/kg at
the same times as the MnCl2 injection. The LPS mice injected with MnCl2 are designated
as LPS + MnCl2 hereafter, and the LPS mice injected with saline are designated as LPS +
saline. The sham-operated mice with i.c. PBS injection are designated as PBS + MnCl2.
One day after LPS or PBS injection, six LPS + MnCl 2 mice, five LPS + saline mice and
five PBS + MnCl2 mice were scanned using MRI. The remaining mice were scanned
seven days after LPS or PBS injection. After MRI, the mice were euthanized and brains
were removed for histology.
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MRI was performed 24 hours after the last MnCl2 injection on a 7T/21 cm
horizontal bore scanner (Bruker, Billerica, MA) operating ParaVision 5.1 with a volume
coil for RF transmission and a 4-channel phased-array coil for signal reception. Mice
were scanned using T1 mapping (fast spin echo with variable TR from 0.4 s to 10 s, 12
slices, slice thickness = 0.5 mm, in-plane resolution = 0.1x0.1 mm2) and T1-wt MRI
(gradient recalled echo, TR = 20 ms, flip angle = 20o, 3D isotropic resolution = 0.1 x 0.1
x 0.1 mm3).
To reduce the influence of the inhomogeneous signal reception by the surface
coil, N3 field inhomogeneity correction [36] was first performed on each image using
MIPAV (CIT, NIH). The brain was then manually aligned to the LONI atlas (LONI,
UCLA) in Analyze (AnalyzeDirect, KS). The alignment is necessary for accurate
quantification of signal enhancement due to manganese uptake.
MRI signal enhancement was measured on a slice-by-slice basis in the axial
direction. On each slice, the injection site was first identified. The mean value and
standard deviation (SD) of the signal intensity about the corresponding location of the
needle hole on the contralateral hemisphere was measured (in a larger ROI), then the
intensity threshold was defined as the mean value plus 2 SDs. This threshold was applied
on the ipsilateral hemisphere as the lower boundary to identify enhanced area about the
needle hole. The enhanced volume was the summation of the enhanced areas multiplied
by the slice thickness. The total enhanced volume was then normalized to the needle
depth. The signal enhancement ratio was calculated by dividing the mean signal intensity
in the enhanced volume by mean intensity on the contralateral side.
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2.2.6. Immunohistology
Mice were euthanized immediately after MRI. Brains were collected and fixed in 4%
paraformaldehyde overnight and embedded in paraffin. The paraffin blocks were cut into
5 μm thick sections. These brain tissue sections were then labeled with rabbit polyclonal
antibodies for glial fibrillary acidic protein (GFAP) (1:1000, Dako, Carpinteria, CA).
Microglia were stained with rabbit polyclonal antibodies for ionized calcium binding
adaptor molecule 1 (Iba-1) (1:500; Wako Chemicals, Richmond, VA). The polymerbased HRP-conjugated anti-mouse and anti-rabbit Dako EnVision systems were used as
secondary detection reagents and 3,3’-diaminbenzidine (DAB, Dako) used as a
chromogen. All paraffin-embedded sections were counterstained with Mayer's
hematoxylin. Images were captured with a 10x objective using Nuance EX multispectral
imaging system fixed to a Nikon Eclipse E800 (Nikon Instruments, Melville, NY), and
image analysis software (Caliper Life sciences, Inc., a Perkin Elmer Company,
Hopkinton, MA) was used for quantification of GFAP and Iba-1 expression in the region
of interest (in and around the injection line) as reflected by intensity/µm 2. Area-weighted
average intensity was calculated for GFAP and Iba-1 expression by dividing the total
signal intensity, for each partitioned area, by area (µm2).
For immunofluorescence labeling, brain sections about the injection line were
treated with the paired combination of primary antibodies mouse anti-synaptophysin
(SYN) (1:1000, EMD Millipore), and rabbit anti-microtubule-associated protein 2
(MAP2) (1:750, EMD Millipore). Primary antibodies were labeled with secondary antimouse and anti-rabbit antibodies conjugated to the fluorescent probes Alexa Fluor 488
and Alexa Fluor 594, and nuclei were labeled with DAPI (4,6-diamidino-2-
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phenylindole). Slides were coverslipped with ProLong Gold anti-fade reagent
(Invitrogen, Carlsbad, CA). Then slides were stored at −20°C after drying for 24 hours at
room temperature. Images were captured at wavelengths encompassing the emission
spectra of the probes, with a 10X objective by Nuance EX multispectral imaging system
fixed to a Nikon Eclipse E800 (Nikon Instruments, Melville, NY), and image analysis
software (Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) used for
quantification. For SYN and MAP2 expression, area-weighted average fluorescence
intensity was calculated in the region of interest (in and around the injection line) by
dividing the total signal intensity, for each partitioned area, by area (µm2) as
intensity/µm2.

2.2.7. Statistical Analysis
T-test was used to compare the cell manganese concentrations in the in vitro study.
Correlation between manganese uptake by PC-12/glial cells and cytokine level were
performed using Pearson’s correlation coefficient calculation. In the in vivo MEMRI
study, t-test was used to compare all the variables in between LPS and PBS injected
groups, whereas Pearson’s correlation coefficient was used to test for correlations between
signal enhancement and glial reactivity.

2.3. Results
2.3.1. Mn2+ Uptake by PC-12 Cells
The manganese concentration in PC-12 cells co-cultured with astrocytes and microglia
was shown in Fig. 2.2.a and 2.2.b, respectively. Mn2+ concentration in PC-12 cells was
plotted against cytokine level (IFN-/TNF-α, ng/ml) at 2 and 15 hours of MnCl2
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incubation time (left and right plots, respectively). In this figure, several properties of the
baseline manganese uptake by PC-12 cells (when IFN-/TNF-α = 0/0) are manifest. First
of all, the measurements at MnCl2 concentration = 0 shown in Fig. 2.2 by dash-dot lines
demonstrated that PC-12 cells endogenous manganese was low, suggesting the
manganese in PC-12 must be taken from the extrinsic source – the MnCl2 solution.
Secondly, the manganese uptake by PC-12 cells depends on the availability of the
extrinsic manganese (i.e., the concentration of MnCl2 solution). It can be seen that the
PC-12 manganese concentration is positively correlated with MnCl2 concentration in all
the plots in Fig. 2.2 (Pearson’s correlation, r ≥ 0.900, p < 0.05). The incubation time of
MnCl2 apparently plays a role in PC-12 manganese uptake as well. The manganese
concentration in PC-12 cells at 15 hours was much higher than at 2 hours, evidenced by
comparing the left and right columns in Fig. 2.2 (p < 0.05 at MnCl2 = 160 and 320 µM).
These observations were in agreement with previous findings [3].
The role of glial reaction on PC-12 manganese uptake involves a number of
factors including the glial cell type, and the level and time of glial reaction. Fig. 2.2.a
illustrates that the change in PC-12 manganese uptake resulted from astrocytic activation.
At short inflammatory cytokine treatment time (2 hours), PC-12 manganese uptake was
almost linearly increased with cytokine levels at 160 µM (Pearson’s correlation, r =
0.990, p < 0.01) and 320 µM (Pearson’s correlation, r = 0.998, p < 0.01). Prolonged
treatment (15 hours) seemed to suppress the manganese uptake by PC-12 cells with
cytokine levels at 160 and 320 µM MnCl2. However the negative correlation between the
manganese concentration and cytokine level was not significant (p = 0.064 at 160 µM, p
= 0.052 at 320 µM).
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On the other hand, microglial reaction had no significant impact on PC-12
manganese uptake. At the high MnCl2 concentration (320 µM) and short treatment time
(2 hours), it showed the trend of negative impact (Pearson’s correlation, r = -0.935, p =
0.065). The PC-12 manganese uptake remained constant at all other MnCl2
concentrations at both 2 and 15 hours.
It was interesting to see that at 15 hours Mn2+ uptake by PC-12 cells co-cultured
with astrocytes at baseline (IFN-γ/TNF-α = 0/0) was twice the concentration of Mn2+ as
PC-12 cells co-cultured with microglia. This result could be due to increase in Mn2+
efflux from astrocytes in response to high extracellular Mn2+ [37], which could cause
increase in extracellular Mn2+ concentration, and thus lead to more Mn2+ uptake by PC-12
cells.

2.3.2. Manganese Uptake by Glial Cells
No significant exogenous manganese uptake by glial cells was observed in this study at
any extracellular MnCl2 concentration, glial activation level, or times of exposure (data
not shown). The ICP/MS measurements showed that the intrinsic manganese content in
astrocytes and microglia was 50-70 ppb, which is about 30-50 times higher than that of
PC-12 cells at baseline (measured at 0 µM MnCl2). The intrinsic manganese
concentrations of glial cells measured in this work are in agreement with previous studies
[38,39]. The high intrinsic Mn2+ concentration in glial cells indicates that Mn2+ is an
important element for the function of glial cells.

2.3.3. MRI Signal Enhancement and Enhanced Volume Measurements
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At Day 1 after LPS/PBS injections, signal enhancement was found only in 2 mice in each
group. Signal enhancement at Day 1 was negligible as compared to Day 7, and was not
significantly different between the LPS + MnCl2 and PBS + MnCl2 groups (Data not
shown). At Day 7 after LPS injection, T1-wt images of the LPS + MnCl2 group showed
strong signal enhancement around the injection line compared to both the surrounding
tissue and the corresponding region in the contralateral hemisphere. The T1-wt image of a
Day 7 LPS + MnCl2 mouse was shown in Fig. 2.3.a in three orthogonal planes: coronal
(upper left), sagittal (upper right) and axial (bottom left). The areas around the injection
line were encased by red boxes and shown in magnified windows in Fig. 2.3.a. The signal
enhancement in this area was robust. The T1-wt image of a PBS + MnCl2 mouse was
shown in Fig. 2.3.b. The PBS injected mice showed minimal enhancement compared to
the LPS injected mice. The enhancement ratios calculated in the PBS + MnCl2 and LPS +
MnCl2 groups are shown in Fig. 2.3.c. Statistical analysis showed significantly higher
signal enhancement ratio in the LPS + MnCl2 group as compared to the PBS + MnCl2
group, p < 0.01. Similarly as shown in Fig. 2.3.d, enhanced tissue volumes (after
normalization by injection depths) were significantly larger in the LPS + MnCl 2 group
than in the PBS + MnCl2 group, p < 0.001. There was no obvious signal enhancement in
the mice injected with only LPS but not MnCl2 (the LPS + saline group) as shown in Fig.
2.3.e.

2.3.4. Immunohistology
At Day 1 after LPS/PBS injection, no reactive astrocytes were found, and only microglia
detected by Iba-1 were observed in LPS injected mice around the injection line. A brain

46
slice of a LPS + MnCl2 mouse at Day 1 is shown in Fig. 2.4.a. The Iba-1 staining on a
region around the injection line (red box) is shown in a magnified (20X) window. As
described in the preceding paragraph, no significant MEMRI signal enhancement was
observed in these mice (data not shown). Both astrocytic and microglial reactivity were
detected at Day 7 in LPS injected mice. The top row in Fig. 2.4.b shows a brain slice of a
LPS + MnCl2 mouse at Day 7. The GFAP and Iba-1 staining on a region around the
injection line are shown in magnified (20x) windows. It can be seen that a large number
of activated astrocytes were detected by GFAP, and activated microglia by Iba-1, in this
region. A brain slice of a PBS + MnCl2 mouse is shown in the 2nd row in Fig. 2.4.b. The
areas stained by GFAP and Iba-1 in the region about the injection line (red box) were
much smaller compared to the LPS + MnCl2 mouse. In quantitative analysis, at Day 7,
the astrocytic reactivity represented by GFAP expression (p < 0.01) and microglial
reactivity by Iba-1 expression (p < 0.05) were significantly higher in the LPS + MnCl 2
group than in the PBS + MnCl2 group (Fig. 2.4.c). Immunofluorescence labeling for
neuronal markers (SYN and MAP2) showed no significant difference in neuronal loss
between LPS + MnCl2 and PBS + MnCl2 groups around the injection lines (data not
shown).
Fig. 2.5.a shows that the correlation between astrocyte and microglial reactivity is
significant (Pearson’s correlation coefficient, r = 0.62, p < 0.05) in the LPS + MnCl2
group at Day 7. More interesting is that, at Day 7 in the LPS + MnCl2 group, there was a
significant correlation between astrocytic reactivity and enhanced tissue volume
calculated from MEMRI data (Pearson’s correlation coefficient, r = 0.66, p < 0.05) as
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shown in Fig. 2.5.b. No correlation was found between microglial reactivity and
enhanced tissue volume.
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(a)
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Figure 2.2. Mn2+ concentration in PC-12 cells co-cultured with astrocytes plotted against
cytokine treatment level (IFN-γ/TNF-α, ng/ml) at 2 hours (Left) and 15 hours (Right) of
MnCl2 incubation. (b) Mn2+ concentration in PC-12 cells co-cultured with microglia
plotted against cytokine treatment level (IFN-γ/TNF-α, ng/ml) at 2 hours and 15 hours of
MnCl2 incubation.
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Figure. 2.3. T1-wt images and enhancement quantification. (a) T1-wt image of a PBS +
MnCl2 mouse. The image was shown in sagittal, coronal and axial directions (counterclockwise starting from upper right). Areas around the injection line were encased by red
boxes and shown in magnified windows. (b) T1-wt image of a LPS + MnCl2 mouse. (c)
T1-wt image of a LPS only (no MnCl2 injection) mouse. No obvious signal enhancement
was observed in the mice injected with only LPS but not MnCl2. (d) Enhancement
measurements. The LPS + MnCl2 group showed significantly higher signal enhancement
than the PBS + MnCl2 group (p<0.01). (e) Enhanced volume. Enhanced volumes
(normalized by dividing it by respective Injection depths). The LPS + MnCl 2 group
showed significantly larger enhanced volumes (p<0.01).
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Figure. 2.4. Immunohistology. (a) A brain section of a LPS + MnCl2 mouse at Day 1
after LPS injection. The reactive microglia by Iba-1 in the regions encased in red boxes
about the injection line are shown at 20x. (b) A brain section of a LPS + MnCl2 mouse
(top row) and of a PBS + MnCl2 mouse (2nd row). The reactive astrocytes by GFAP and
microglia by Iba-1 in the regions encased in red boxes around the injection line are
shown at 20x. (c) Glial reactivity quantification. Astrocytic and microglial reactivity
represented by GFAP and IBa-1 expressions (Intensity/µm2) were significantly higher in
the LPS + MnCl2 group compared to the PBS + MnCl2 group (p < 0.01 and p < 0.05,
respectively)
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(a)

(b)

Figure. 2.5. Correlation comparisons. (a) Correlation between astrocytic and microglial
reactivity (r = 0.62, p < 0.05). (b) Correlation between astrocytic reactivity and enhanced
volume (r = 0.66, p < 0.05)
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2.4. Discussion
Intrinsic manganese content in neurons is low compared to glial cells, and neuronal
manganese uptake is partly dependent on the availability of extrinsic manganese. Here
we investigate the effect of glial reaction on glial and neuronal manganese uptake. The
results suggest that inflammatory cytokine induced astrocytic activation [40] stimulates
Mn2+ uptake of neurons, and that this uptake is proportional to the level of activation. On
the other hand, microglial reaction has no direct effect in stimulating neuronal Mn 2+
uptake, and intensive microglial reaction may even suppress uptake.
The intrinsic manganese content in astrocytes and microglia is much higher than
in PC-12 cells as shown in this study and others [38,39]. The high intrinsic Mn2+
concentration in glial cells indicates that Mn2+ is an important element for the function of
these cells. Studies have found that activity of several enzymes in the central nervous
system is Mn2+ dependent, such as superoxide dismutase, ATPase, and glutamine
synthase [37]. No significant exogenous Mn2+ uptake by glial cells was observed in this
study at any extracellular MnCl2 concentration or glial activation level or time.
The in vivo imaging study was designed to reveal the effects of microglial and
astrocytic reactions on MEMRI signal enhancement. The imaging times of Day 1 and
Day 7 were chosen because, after one day of LPS injection, microglial reaction is well
defined, and astrocytic reaction generally takes place after three-four days, and becomes
well established around seven days.
The in vivo study has clearly demonstrated the co-localization and strong
correlation between reactive astrocytes and MEMRI signal enhancement. By
incorporating the in vitro finding that reactive astrocytes stimulate neuronal manganese
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uptake rather than absorb manganese themselves, we are confident to conclude that the
MEMRI signal enhancement resulted from the elevated manganese uptake in neurons
stimulated by astrocytic reaction.
In GFAP stained brain slices, we also found activated astrocytes in regions remote
from the injection line in the LPS + Mn2+ mice. However the number of the activated
astrocytes in these regions was small. The neuronal Mn2+ uptake caused by these
astrocytes was not detected in MRI due to the limited sensitivity.
Several groups have studied the relationship between MEMRI signal
enhancement and glial reaction in a range of animal models of human disease, including
but not limited to, cathepsin D deficiency [26], epilepsy [8], ischemia [14,22,27]and
prenatal X-ray exposure [9]. However, results have been varied. Some studies showed
elevated MEMRI signal enhancement co-localized with activated microglia [26] or both
activated microglia and astrocytes [14,22,27]. However the study of prenatal X-ray
exposure [9] found negative correlation between brain tissue longitudinal relaxivity (R1)
and reactive astrocytes. Because R1 determines MEMRI signal intensity, this study
suggested that astrocytic reaction suppressed signal enhancement. Another study of
epilepsy [8] found no correlation between MEMRI signal change and astrocytic reaction.
The inconsistent results from these studies could be due to the variety of disease models
used. In these diseases, a variety of pathobiological events occur in addition to glial
reaction, such as cell swelling and necrosis [14,22,27], apoptosis [26], and hippocampal
mossy fiber spouting [8]. These events can impair neurons that could either stimulate or
suppress neuronal Mn2+ uptake, causing inconsistent MEMRI signal enhancement. One
particular study [24] using rats, found strong positive correlation between MEMRI signal
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enhancement and astrocytic reaction in a stroke model, and proposed that the signal
enhancement is caused by Mn2+ accumulation in reactive astrocytes through voltagegated Ca2+ channels. However, this study did not investigate the neuronal reaction to glial
activation, and thus cannot exclude the contribution of elevated Mn2+ uptake by reactive
neurons to signal enhancement.
Astrocytes react rapidly to various neurodegenerative insults. Reactive astrocytes
protect neurons by secluding the injury site from the rest of the CNS area, and secreting
multiple neurotrophic factors to aid neuronal survival. However, the astrocytic processes
have been implicated in the pathogenesis of a variety of neurodegenerative diseases,
including but not limited to, Alzheimer’s disease, Parkinson’s disease, HIV-associated
neurocognitive disorders, acute traumatic brain injury, and inflammatory demyelinating
diseases. It is believed that rapid and severe astrocytic reaction initiates or augments
inflammatory response by secreting various pro-inflammatory molecules leading to
neuronal death and brain injury [40].
Monitoring glial-neuronal interactions dynamically using noninvasive imaging
technologies is a unique and powerful method, which can be used to understand the
pathobiology of neurodegenerative diseases, provide diagnosis and prognosis, and aid in
the development of therapeutic methods. MRI is a noninvasive imaging technology
providing high spatial resolution, excellent soft tissue contrast and real-time
measurements. Because Mn2+ crosses the brain-blood barrier and enters neurons through
voltage-gated calcium channels [41], MEMRI has proven to be a powerful tool to study
neuronal viability, activation and impairment. The results in this study show the potential
to use MEMRI monitoring of glial-neuronal interactions in normal and abnormal
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conditions. Our immunohistological results showed no significant neuronal death caused
by LPS injection at the times when MEMRI was performed. In the future we plan to
extend the study to later stages at which neuronal death induced by glial reaction occurs.
We expect to see decreased MEMRI signal enhancement due to the neuronal death as
shown in several previous studies [10,11,13]. Therefore a longitudinal MEMRI study
showing neuronal excitation by astrocytic reaction and neuronal death later provides
valuable information of the progression of pathobiology.
In conclusion, we demonstrated that astrocytic reaction induces elevated neuronal
Mn2+ uptake that results in MEMRI signal enhancement. This study demonstrates that
MEMRI can be used not only to monitor neuronal vitality and activity but also to monitor
astrocyte-neuronal interactions in animal model systems of neurodegenerative diseases.
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CHAPTER - 3
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI)
Detects Brain Pathology in Animal Models of
Neurodegenerative Diseases
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3.1. Introduction
HIV-1-associated neurocognitive disorders (HAND) is a clinical disorder that reflects the
cognitive, behavioral and motor dysfunctions associated with progressive viral infection
[1]. HAND reflects a spectrum of clinical abnormalities that include asymptomatic

neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and HIVassociated dementia (HAD) [2]. Although antiretroviral therapy (ART) has significantly
decreased the HAD incidence and prevalence, ANI and MND are seen in half of infected
patients [3] and as such continues to be a significant quality of life complication of
HIV/AIDS [4,5]. Despite advances in the understanding HIV neuropathobiology, disease
diagnosis is made by exclusion of co-morbid conditions such as drug abuse,
neurodegenerative and psychiatric disorders, opportunistic infections and malignancies
[6]. Moreover, levels of viral replication and cognitive impairment are not always linked

nor do they provide clear relationships between neuropathology and cognitive function
[4]. It is possible that diagnostic clarity could be provided through imaging biomarkers.

In attempts to detail HIV-associated neuropathology, our laboratories pioneered
the development of murine models of virus-associated brain disease [7]. Specifically, we
show that humanized mice reconstituted with CD34+ human hematopoietic stem cells
reflect the consequences of viral infection and consequent immune deterioration in its
human host [8-11]. In this model, human progenitor cells are transplanted into genetically
modified immunodeficient NOD/scid-IL-2Rγcnull (NSG) mice [12]. Such mice support
persistent HIV-1 infection leading to behavioral and motor impairments paralleling
Reproduced with permission from Bade AN, Gorantla S, Dash PK, Makarov E, Sajja BR, Poluektova LY,
Luo J, Gendelman HE, Boska MD, Liu Y; Manganese-Enhanced Magnetic Resonance Imaging Reflects
Brain Pathology During Progressive HIV-1 Infection of Humanized Mice; Mol Neurobiol. 2015, Jun 11;
Copyright Springer
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neuronal and glial responses [13]. Our recent works demonstrated that brain imaging such
as proton magnetic resonance spectroscopy (1H MRS) and diffusion tensor imaging
(DTI) can uncover the neuropathological consequences of chronic HIV-1 infection in
these mice [8,13].
A significant advantage for manganese-enhanced magnetic resonance imaging
(MEMRI) over other magnetic resonance imaging (MRI) modalities rests in the ability to
directly map voltage-gated calcium channel activity through manganese ions (Mn2+)
neuronal accumulation. As Mn2+ is a calcium (Ca2+) analogue, it can enter neurons by
voltage-gated Ca2+ channels[14] and can be moved anterograde by axonal transport and
microtubule assembly [15,16]. Mn2+ is an excellent T1 shortening contrast agent affording
relatively high spatial resolution and signal-to-noise ratio within reasonable scanning
time [17,18]. Administration of Mn2+ generates enhanced signal intensity on T1-wt
images. The signal enhancement is associated with neuronal activities. MEMRI can
assess neuronal well-being for anatomical, integrative, functional and axonal transport
activities of nerve cells and their connections [14,19]. Herein, we demonstrate that
MEMRI facilitates precise noninvasive high spatial resolution (100 μm3 isotropic)
determinations of brain regions of HIV-1 incited neuroinflammation and neuronal injury
in NOD/scid-IL-2Rγcnull humanized mice. Correlations between immunocytochemical
measures of brain disease and MEMRI signal enhancement are operative.

3.2. Materials and Methods
3.2.1. Murine neuroAIDS model
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NOD/scid-IL-2Rγcnull (NSG) mice were bred under specific-pathogen-free conditions in
accordance with the ethical guidelines at the University of Nebraska Medical center
(UNMC), Omaha, Nebraska. Human cord blood obtained with parental written informed
consent from healthy full-term newborns (Department of Gynecology and Obstetrics,
UNMC) was utilized for CD34+ cells isolation using immune-magnetic beads according
to the manufacturer's instructions (CD34+ selection kit; Miltenyi Biotec Inc., Auburn,
CA). Numbers and purity of human CD34+ cells were evaluated by fluorescenceactivated cell sorting (FACS). Cells were either frozen or immediately transplanted into
newborn mice at 105/mouse intrahepatically (i.h.) in 20 μl phosphate-buffered saline
(PBS) using a 30-gauge needle. Newborn mice received human cells from single donors.
On the day of birth, newborn mice were irradiated at 1 Gy using a C9 cobalt 60 source
(Picker Corporation, Cleveland, OH). Starting from 22 weeks after reconstitution, HIV-1
virus was intraperitoneally (i.p.) injected at 104 TCID50 into mice. Humanized mice
without infection served as controls. Number of human cells and the level of engraftment
were analyzed by flow cytometry. In the study, all protocols related to animal
experiments were approved by the Institutional Animal Care and Use Committee
(IACUC), UNMC University and met the requirements of the UNMC University ethical
guidelines, which are set forth by the National Institutes of Health.

3.2.2.Viral load
The automated COBAS Amplicor System V1.5 (Roche Molecular Diagnostics, Basel,
Switzerland) was used to measure the peripheral level of viral RNA copies/ml. Mouse
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plasma (20 µl) was used to dilute with 480 µl of sterile normal human plasma for the
assay. The baseline detection of assay after dilution is 1250 viral RNA copies/ml.

3.2.3. Flow cytometry
Peripheral blood leukocytes, spleen and bone marrow cell suspensions were examined for
anti-human-CD45, CD3, CD4 and CD8 markers. Flow cytometry on peripheral blood
leukocytes was done every other week from the point of infection. At the end of study,
flow cytometry was done for spleen and bone marrow as well. Mouse peripheral blood
samples were collected from submandibular vein (cheek bleed) by using lancets
(MEDIpoint, Inc., Mineola, NY) in EDTA coated tubes. Antibodies and isotype controls
(BD Phar-Mingen, San Diego, CA) were used to stain cells. Staining was analyzed by
using FACSDiva (BD Immunocytometry Systems, Mountain View, CA). Percentages of
total gated lymphocytes were expressed as results.

3.2.4. Immunohistology
At 16 weeks, mice were euthanized immediately after imaging and brains were collected.
Brain tissues were fixed in 4% paraformaldehyde overnight and embedded in paraffin.
Five μm thick brain tissue sections were labeled with mouse monoclonal antibodies for
HLA-DQ/DP/DR (1:100, Dako, Carpinteria, CA), HIV-1 p24 (1:10, Dako), c-Fos (1:50,
Santa Cruz Biotechnology, Santa Cruz, CA), and rabbit polyclonal antibodies for glial
fibrillary acidic protein (GFAP) (1:1000, Dako), ionized calcium binding adaptor
molecule -1 (Iba-1) (1:500; Wako Chemicals, Richmond, VA), Caspase3 (1:10, EMD
Millipore, Billerica, MA). The polymer-based HRP-conjugated anti-mouse and anti-
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rabbit Dako EnVision systems were used as secondary detection reagents, and 3,3’diaminbenzidine (DAB, Dako) was used as a chromogen. All paraffin-embedded sections
were counterstained with Mayer's hematoxylin. Deletion of primary antibodies served as
controls. Images were captured with a 100×, 40× and 20× objectives using Nuance EX
multispectral imaging system fixed to a Nikon Eclipse E800 (Nikon Instruments,
Melville, NY).
For immunofluorescence labeling, brain sections were treated with the paired
combination of primary antibodies mouse anti-synaptophysin (SYN) (1:1000, EMD
Millipore), and rabbit anti-microtubule-associated protein 2 (MAP2) (1:500, EMD
Millipore), mouse anti-neurofilament (NFs) (1:200, Dako) and rabbit anti-GFAP (1:1000,
Dako); additionally, brain sections were treated alone with rabbit anti-Iba-1(1:500).
Primary antibodies were labeled with secondary anti-mouse and anti-rabbit antibodies
conjugated to the fluorescent probes Alexa Fluor 488 and Alexa Fluor 594, and nuclei
were labeled with DAPI (4,6-diamidino-2-phenylindole). Slides were cover-slipped with
ProLong Gold anti-fade reagent (Invitrogen, Carlsbad, CA). Slides were stored at −20 °C
after drying for 24 hours at room temperature. Images were captured at wavelengths
encompassing the emission spectra of the probes, with a 40× objective by Nuance EX
multispectral imaging system fixed to a Nikon Eclipse E800 and image analysis software
(Caliper Life sciences, Inc., a Perkin Elmer Company, Hopkinton, MA) was used for
quantification of SYN, MAP2, NF and GFAP expression. Area-weighted average
fluorescence intensity was calculated in the region of interest (ROI) by dividing the total
signal intensity, for each partitioned area, by area (µm2) as intensity/µm2. Images were
also captured with LSM 710 microscope using a 40X oil lens (Carl Zeiss Microscopy,
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LLC, NY, USA). Expression of cFos was scored (out of 10) by two investigators using
20× objective in blinded manner. Findings were compared to animals that were not
manipulated (score 0). Student’s t-tests were performed to compare immunohistological
results of the HIV-1 infected animals with controls.

3.2.5. MEMRI
MnCl2·4H2O (Sigma-Aldrich, St Louis, MO) was added to 0.9% w/v NaCl (Hospira,
Lake forest, IL) to make 50 mM MnCl2 solution. MnCl2 solution was administrated i.p.
with the dose of 60 mg/kg consecutively four times at 24 hour intervals before MRI.
After the injection, the mouse was observed daily to detect the side effects of MnCl2.
MRI data were acquired 24 hours after the last MnCl2 administration on Bruker
Bioscan 7 Tesla/21 cm small animal scanner (Bruker, Billerica, MA) operating
Paravision 5.1 with a 72 mm volume resonator and a 4-channel phased array coil. Mice
were anesthetized by inhalation of isoflurane in 100% oxygen and maintained 40-80
breaths/minute. Mice were scanned using T1 mapping sequence (fast spin echo with
variable repetition time (TR) from 0.4 s to 10 s, 12 slices, slice thickness = 0.5 mm, inplane resolution = 0.1 × 0.1 mm2) and T1-wt MRI (FLASH, TR = 20 ms, flip angle = 20o,
3D isotropic resolution = 0.1 × 0.1 × 0.1 mm3). After MRI, the mice were euthanized and
tissues were removed for immunohistological study. The same scan was also performed
before the MnCl2 administration, and the acquired image was used as baseline data for
the calculation of signal enhancement.

3.2.6. MRI data pre-processing
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To reduce the influence of the inhomogeneous signal reception on the T1-wt images by
the phased array surface coil, N3 field inhomogeneity correction [20] was first performed
on each image using MIPAV (CIT, NIH). The brain volumes in the T1-wt images were
extracted using an in-house Matlab program [21] based on the level sets method. The
brain images were then registered to a MEMRI-based NSG mouse brain atlas developed
in our laboratories using affine transformation first, and then nonlinear transformation
(DiffeoMap, John Hopkins University, Baltimore, MD).
To calculate Mn2+ induced T1-wt signal enhancement, the MRI system variations
between the baselines and post MnCl2 injection scans need to be minimized. This is
achieved by calibrating the baseline and post Mn2+ injection T1-wt images using T1
values. A detailed description of the MEMRI enhancement calculation and T1-wt image
calibration are described in the MEMRI signal enhancement and tissue manganese
concentration part of the methods and material section of this chapter. The T1 maps were
first generated using an in-house Interactive Data Language (IDL) version 8.2 (Exelis
Visual Information Solutions, Boulder, Colorado) program from the data acquired by T1
mapping sequence. ROIs were then placed on relatively uniform tissue regions including
frontal cortex and caudate on T1 maps and T1-wt images. The baseline and post Mn2+
injection longitudinal relaxivity (R1blROI and R1MnROI) and T1-wt signal intensity (SblROI
and SMnROI) in the ROIs were measured. The calibration factor was calculated as C =
(SMnROI/SblROI) × (R1blROI/R1MnROI). The baseline T1-wt image (Sbl) was then calibrated
using the calibration factor C : SblC = Sbl × C.

3.2.7. MEMRI signal enhancement and tissue manganese concentration
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In this study, MEMRI enhancement is defined as (SMn – Sbl)/SMn, where Sbl and SMn are
the baseline (bl) and manganese enhanced (Mn) signal, respectively. The spoiled FLASH
(Fast Low Angle SHot) sequence was used to acquire T1-wt images in this study. The
signal generated using FLASH can be expressed as:

(1),

where M0 is the spin density, TR and TE are repetition and echo time, respectively. α is
the flip angle. Therefore, the baseline and manganese enhanced signal are

(2),
and
(3).
The ratio of the manganese enhanced and baseline signals is
(4).

T2 reduction caused by manganese administration is much less pronounced than T1
reduction. A previous study showed that in rat cortex, the T2 reduction is about 10% at 24
hours after MnCl2 injection, while T1 reduces approximately 30% (Chuang KH et al.,
Magnetic Resonance in Medicine, 2009, doi: 10.1002/mrm.21962, PMID:19353652). TE
is also relatively short as well (=3 ms) in this study. Therefore Eqn (5) can be simplified
as

(5)
Recall the Taylor expansion:
(6).
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Replace x with

in Eqn (6):
,

(7),

and since TR (= 20 ms) / T1 (> 800 ms in most regions after manganese administration) is
small, the second and higher order terms in Eqn (7) can be ignored, that is,
. Applying this equation in Eqn (5) and after skipping several
steps, Eqn (5) can be further simplified:

(8).

The third terms in both numerator and denominator are at the second order, and thus can
be dropped similarly to in Eqn (7):

(9),

where R1 is the relaxitivity, and R1 = 1/T1. Eqn (9) means that the ratio of the signals
acquired before and after manganese administration is equal to the ratio of relaxivities.
As R1Mn = R1bl + r1*[Mn], where r1 is the molar relaxivity (s-1 mM-1) of manganese, and
[Mn] is the manganese concentration in mM, Eqn (9) can be rewritten as

(10).
Replacing 1 with Sbl/Sbl and subtracting one from each side:
(11).

From Eqn (11), we can see the tissue manganese concentration [Mn] is proportional to
the normalized signal change induced by manganese administration (i.e., the signal
enhancement).
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MRI scanner system calibration:
System settings such as RF coil, analogue-to-digital converter, and environment temperature can
change in the post-manganese administration imaging session from the pre-administration
session. The variation can be minimized by calibrating the system using relaxation times
measured before and after manganese administration. If we assume that the effect of the system
variation is a constant C (calibration factor) and set system parameter of the post-manganese
session as 1, then the acquired baseline signal is Sacq = CSbl. From Eqn (9),

(12).
T1bl and T1Mn were measured using a fast spin echo sequence with variable TR in this study. Using
C from Eqn (12), Sbl can be calculated: Sbl = Sacq / C.

3.2.8. MEMRI enhancement analysis
The Mn2+ induced T1-wt signal enhancement was calculated by: (SMn – SblC) / SblC. A
pixel-by-pixel comparison was first performed between the HIV-1 infected mice and the
control group using Student’s t-test, followed by a brain region specific analysis. Using
the MEMRI-based brain atlas, the T1-wt signal enhancement on 41 brain regions/subregions was calculated. The student’s t-test was performed to exam the significance of
enhancement change in each HIV-1 infected brain region compared to the control group.
The association between MRI signal changes, plasma viral load, T-cells and
immunohistological results in HIV mice was examined using Pearson product-moment
correlation. The association between enhancement and quantified GFAP, Iba-1, MAP2,
NF and SYN staining was studied on the CA1, CA3 and DG brain regions. Time course
of infection that included measures of the plasma viral load at the time of animal sacrifice
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(16 WPI), its rate of change (slope) over time, and change in maximum and end time
viral levels were measured. These parameters tested over time were correlated with MRI
signal enhancements. The T-cell parameters that were measured over time included
blood, spleen and bone marrow CD4 and CD8 positive T cell numbers.

3.2.9. Brain structure volumetric analysis
In the MRI data pre-processing, the brain images were registered to the MEMRI-based
brain atlas. The 41 brain regions were identified on each brain image. The brain images
were transferred back to their original spaces employing the inverse of the transformation
matrices calculated for registration. The volumes of the regions were calculated in the
original spaces. Student’s t-tests were performed to compare the volumes of the HIV-1
infected animals with controls.

3.2.10. Detection of Mn2+ toxicity
Animals were observed daily after each i.p. MnCl2 injection and 24 hours after the
injection. If tremor or convulsion (the signs of manganese overdose) persisted longer than
3 minutes or lethargy observed at 24 hours, mice were euthanized.

3.3. Results
3.3.1. HIV-1 Infection of humanized mice
Humanized mice (n = 8) were infected with the HIV-1ADA at 22 weeks of age (Fig. 3.1.a).
Viral and immune parameters were assessed then compared against controls (uninfected
humanized mice, n = 7). Flow cytometry was performed at 2, 4, 7, 10, 13 and 16 weeks
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post infection (WPI) to determine reconstitution of peripheral human immune cells
(CD45, CD3, CD4, CD8). The temporal changes of CD4+ and CD8+ T cells in infected
humanized mice are shown in Fig. 3.1.b. The steady CD4+ T cells decline and
concomitant increases in CD8+ T cells were readily seen in HIV-1 infected mice. Control
uninfected animals showed no changes in T cell numbers throughout the study period
(Fig. 3.1.b). Plasma viral RNA copies/ml (viral load, VL) measures were performed at 2,
7, 16 WPI (Fig. 3.1.c). These VL values peaked at the 2nd week after HIV-1 infection and
were sustained throughout the experimental observation period.

3.3.2. Leukocyte brain infiltration
Brain infiltration of human cells including those HIV-1 infected were assessed by
immunohistochemical assays. At 16 WPI, brain sections at 5 µm thickness were stained
for human HLA-DR and HIV-1p24. Human HLA-DR+ cells infiltrated the brains of
infected and control mice were seen in the meninges and perivascular spaces (Fig. 3.1.d).
Few HIV-1p24+ human cells were observed in these regions of infected mice (Fig. 3.1.e).
Glial responses were assessed by glial fibrillary acidic protein (GFAP, astrocyte) and
ionized calcium binding adaptor molecule-1 (Iba-1, microglia) staining. Cortical areas
with hypertrophic astrocytes and morphological features of activated microglia were
readily observed (Fig. 3.1.f). Such activated glial morphologies were not seen in control
animals.

3.3.3. MEMRI
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To track neuropathology induced by continuous HIV-1 infection, MEMRI was performed
at 16 WPI (Fig. 3.1.a). The averaged MEMRI image of the control mice is shown on
coronal brain slices as an anatomical reference in the left column of Figure 3.2.a.
Positions of the coronal slices are depicted using a sagittal slice (top of the left column).
Standard tissue signal enhancement induced by Mn2+ was readily seen within the
olfactory bulb, cerebral cortex, hippocampus, and cerebellum [19]. The color-coded
average enhancement maps of the control and HIV-1 infected mouse brains are illustrated
in the second and third columns of Figure 3.2.a, respectively. The enhancement
represented the signal change induced by Mn2+ normalized to the MRI signal of pre-Mn2+
administration. MEMRI enhancement changes were observed throughout the brain in
HIV-1 infected animals compared to controls (Fig. 3.2.a). Statistically significant
increases in the MEMRI enhancement are shown by pixels with p < 0.05 (the first
column in Fig. 3.2.b). These p values are color-coded and overlaid on the averaged
MEMRI slices. Using the MEMRI-based mouse brain atlas, 41 brain regions/sub-regions
were identified for each humanized mouse. A list of regions on the brain atlas can be
found in chapter 4 (Table 4.1). The MEMRI enhancement was compared between each
brain region of control and HIV-1 infected mouse. The regions with p values less than
0.05 from such comparisons are shown in the second column in Figure 3.2.b and
illustrated with identical color-coding as in the first column. The brain regions with
significantly increased signal enhancement (p < 0.05) are also included within Table 3.1.
Three-dimensional images of brain regions with significant enhancement increase are
illustrated in Figure 3.2.c. The brain regions showing trends of enhancement increase are
listed in Table 3.2. Morphological and volumetric changes were assessed in virus-
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infected animals by the MEMRI mouse brain atlas. Whole brain and regional volumes in
the HIV-1 infected mice were comparable to control animals (data not shown). The
toxicity of Mn2+ was considered. Mice were observed daily after i.p. MnCl2 injections.
This included chemical injection linked tremor and lethargy, the clinical signs of Mn2+
overdose. No Mn2+ induced toxic signs and symptoms were observed during the study.

3.3.4. Immunohistology
Immunohistochemistry was subsequently performed on CA1, CA3 and the dentate gyrus
(DG) regions of the hippocampus at study termination, 16 WPI (Fig. 3.1.a). Brain
sections were stained for GFAP, Iba-1, cFos (neuronal activation), synaptophysin (SYN,
synaptic vesicle protein), and neurofilament (NF, neuronal cytoskeleton protein).
Fluorescence intensity for these antigens was expressed as intensity/µm2. Activated
morphologies were observed as defined by increased cell body size and process
formations for both astrocytes and microglia in virus-infected animals (Fig. 3.3.a and
3.3.b). The presence of activated astrocytes and microglia are known to be linked to
virus-induced inflammation [22,23]. Neuronal activation (cFos expression) was
substantially higher in brain regions with gliosis and specifically in the hippocampus;
indicating increased neuronal excitation during inflammation (Fig. 3.3.c, Fig. 3.5).
Irregularly shaped and decreased SYN expression was seen in the CA3 region of infected
animals and reflected synaptic injury (Fig. 3.3.d). Reduction in NF fibers was also
observed at CA3 region in infected animals (Fig. 3.3.e). NF and SYN expression
demonstrates

neuronal

injury

after

glial

inflammation.

Co-localized

MEMRI

enhancement in infected animals was compared to controls and confirmed the sensitivity
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of the MEMRI in reflecting glial and neuronal histochemical and morphological changes
(Fig. 3.3.f).
Quantitative immunohistochemistry was used to compare neuropathology
between control and HIV-1 infected mice and its association with MEMRI regional
enhancements. In CA1 region, GFAP and Iba-1 expression were significantly higher in
infected animals than controls (GFAP, p = 0.041; Iba-1, p = 0.018); whereas, SYN and
NF expression were not different amongst the groups (Fig. 3.4.a). Gliosis with no
evidence of neuronal injury in CA1 paralleled significant MEMRI signal enhancement
increase in infected animals compared to controls (p = 0.047) (Fig. 3.4.a). In the CA3
region, GFAP expression was higher (p = 0.038), and SYN and NF expression lower
(SYN, p = 0.027; NF, p = 0.005); whereas, Iba-1 signals were not changed by viral
infection (Fig 3.4.b). With a combination of astrocyte responses and neuronal injury,
MEMRI signal remained similar between infected and control animals (Fig. 3.4.b).
GFAP expression was higher (GFAP, p = 0.042) and Iba-1 increased but not significantly
(Iba-1, p = 0.083) in the DG region of infected animals; whereas SYN and NF signals
were not changed (Fig. 3.4.c). MEMRI enhancement in this region was increased in
infected animals (p = 0.045) (Fig. 3.4.c). The quantitative analyses taken together,
demonstrate that activated glia and neurons (increased cFos staining) during
inflammation induced the increase in MEMRI signal in the CA1 and DG brain regions.
However, the enhancement increase was offset by neuronal injury (reduced SYN and NF)
in the CA3 brain region. Microtubule associated protein (MAP2) staining was not
changed in the infected animals. Evidence for neuronal apoptosis determined by anticaspase3 staining was not observed in infected mice (data not shown).
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We next investigated if glial activation and MEMRI signal enhancements were
correlated one with the other. In the CA1 and DG, correlations between GFAP expression
and MEMRI signal increase were seen (CA1, r = 0.86, p = 0.007; DG, r = 0.92, p =
0.001). Linkages between gliosis and MEMRI enhancement demonstrated that Mn2+
uptake and accumulation increases in neurons affected by inflammation. This was
associated with astrocyte responses and the MEMRI signals [24]. Next we measured
relationships between the degree of brain injuries and VL in blood. The average brain
MEMRI enhancement alteration was linked, in measure, to the peripheral VL difference
of at 16 weeks and maximum values (defined as viral load dynamics; r = 0.714, p =
0.071). This result suggested that the greater the viral load drop during the course of
infection, the smaller the MEMRI enhancement change. MEMRI enhancement was not
affected by numbers of CD4+ and CD8+ T cells (data not shown).
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Figure 3.1. (a) The time course of human CD34+ cell reconstitution, HIV-1 infection,
MRI, MnCl2 injections and histopathology. (b) Results from flow cytometric analyses of
human CD4+ and CD8+ cells in peripheral blood of control mice (left) and infected mice
(right). (c) Average HIV-1 RNAs (copies/ml) in peripheral blood of infected mice (n =
8). (d and e) Infiltration of human activated cells detected by HLA-DR (indicated by
arrows, left, 20×) and HIV-1+ cells (detected by p24 antigen) in meninges, parenchyma

84

and perivascular spaces (positive cells indicated by arrows, right, 100×) into the brain of
infected mice at 16 WPI. (f) Brain sections of control and infected mice stained by GFAP
for astrocyte (left, 40×) and by Iba-1 for microglial (right, 40×). Activated glial cell
morphologies were seen in infected animals. Data are expressed as mean
and (C)

SEM in (B)
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Figure 3.2. Comparison of MEMRI enhancement between HIV-1 infected animals and
controls. (a) MEMRI enhancement maps. The first column (from left) shows coronal
slices of the averaged MEMRI of control mice as an anatomical reference. The sagittal
slice (upper left) shows respective coronal positions (red lines). The second column
shows the average enhancement in control mice on the coronal slices. The third column
represents the average enhancement of HIV-1 infected mice. The color bar for the
enhancement maps is at the top of the figure. Dark blue color (0%) means no change in
enhancement from Mn2+ compared to pre-injection signal intensity. Dark red color
represents 120% signal increase compared to pre-injection. Increase in MEMRI
enhancement can be seen throughout the brain of infected animals than controls. (b)
Statistical comparison of MEMRI enhancement between control and HIV-1 infected
animals. The left column shows the pixels with significant enhancement difference (p <
0.05) overlaid onto the averaged brain image. The color bar of p values is at the right.
Dark blue color represents p = 0.05 and dark red color represents the value of 0.00. The
right column shows significantly altered brain regions of infected mice using the same
color scale. (c) Brain regions with significant enhancement changes demonstrated in 3-D.
(1) Averaged brain image. (2) Right hemisphere of the averaged brain. Internal brain
regions can be seen on the middle of sagittal section. (1 and 2) are to provide anatomical
references for the demonstration of regions with significant enhancement changes. (3)
Sub-cortical regions including CA1_CA3_SUB (red) and CP (green). (4) Sub-cortical
regions including DG-mo (red), AMY (orange), PALc (green), and GP (yellow). (5)
Brain stem regions including TH (red), EPI (green), SN (blue) and PRT (purple). (6)
PAG (blue), IC (yellow), SN (red) and PRT (purple). (7) Olfactory regions including
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MOB (red), AOB (green), AON (blue) and PIR (yellow). (8) cc (red) and CBXmo (blue).
The full names of the brain regions are included in Table 3.1.
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Table 3.1. Brain regions that showed significant signal enhancement (p < 0.05)

Sub-cortical
region

Brain stem
region

Olfactory
region
Cerebellar
region
Fiber tracts

Brain regions
CA1_CA2_SUB
DG-mo
CP
AMY
GP
PALc
TH
EPI
P
PAG
IC
SN
RMB
PRT
MOBgl
AOB
PIR
AON
CBXmo

p
0.047
0.046
0.039
0.048
0.028
0.047
0.03
0.043
0.044
0.022
0.01
0.041
0.033
0.043
0.021
0.012
0.046
0.036
0.031

cc

0.037

CA1_CA2_SUB: Field CA1 + Field CA2 + Subiculum of Hippocampus Formation, DGmo: Dentate gyrus_molecular layer, CP: Caudoputamen, AMY: Amygdala, GP: Globus
pallidus, PALc: Pallidum caudal region, TH: Thalamus, EPI: Epithalamus, P: Pons, PAG:
Periaqueductal gray, IC: Inferior colliculus, SN: Substantia nigra, RMB: Rest of midbrain
, PRT: Pretectal region, MOBgl: Main olfactory bulb glomerular layer, AOB: Accessory
olfactory bulb, PIR: Olfactory piriform area, AON: Anterior olfactory nucleus, CBXmo:
Cerebellar cortex molecular layer, cc: corpus callosum, (p < 0.05) (p: t test p value)
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Table 3.2. Brain regions that showed trend of signal enhancement increase
(0.05<= p < 0.01)

Brain regions

p

Isocortex

0.06

STRv

0.065

Sub-cortical

LSX

0.053

region

MS

0.055

DG-(po+sg)

0.071

Brain stem

HY

0.074

region

MY

0.051

Cerebellar

CBXgr

0.053

region

CBwm

0.07

FN

0.071

Isocortex

Isocortex, STRv: Striatum ventral region, LSX: Lateral septal complex, MS: Medial
septal nucleus, DG-(po+sg): Dentate gyrus_(polymorph layer + granular layer), HY:
Hypothalamus, MY: Medulla, CBXgr: Cerebellar granular layer, CBwm: Cerebellar
white matter, FN: Fastigial nucleus
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Figure 3.3. Immunohistology of the hippocampus sub-regions including CA1, CA3 and
DG (40×). Representative brain sections of control and HIV-1 infected mice stained for
GFAP (astrocyte), Iba-1 (microglia), cFos (neuronal activation), SYN (synaptic vesicle
protein), NF (neuronal cytoskeleton protein) and co-localized MEMRI slices are
presented. (a, b and c) Increase in GFAP, Iba-1 and cFos expression was observed in
infected animals compared to controls in all three regions of hippocampus. (d and e) In
CA3 region, SYN and NF expression was decreased (indicated by an oval and arrows,
respectively) of infected animals compare to controls, but not in CA1 or DG. (f) Altered
in MEMRI enhancement in co-localized brain slices was observed in infected animals
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Figure 3.4. Association of immunohistology with MEMRI. (a) Quantitative analysis
showed significant increase in GFAP, Iba-1, and MEMRI enhancement on CA1 region of
HIV-1 infected animals compared to controls. (b) CA3 region showed significantly
increased GFAP, significantly decreased SYN as well as NF, and no change in MEMRI
signal in infected animals compared to controls. (c) DG region showed significantly
increased GFAP, a trend of increased Iba-1, and significantly increased MEMRI
enhancement in infected animals compared to controls. Data are expressed as mean
SEM. (*: p < 0.05, #: p < 0.1)
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Figure 3.5. cFos expression at hippocampus region. HIV-1 infection caused significant
increase in cFos expression compared to control. Data are expressed as mean
p < 0.05)

SEM. (*:
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Figure 3.6. The mechanism of MEMRI in the detection of neuropathology in HIV-1
infected humanized mice. (a) Human immune system reconstitution (humanization) in
NSG mouse. Human CD34+ stem cells (HSC) isolated from umbilical cord blood were
injected intrahepatically into one day old irradiated pups. The injected HSC reach mouse
lymphoid organs including bone marrow and develop into broad range of cell lineages. A
mature human immune system develops in the NOD/scid-IL-2Rγcnull (NSG) mice. (b)
Humanized mouse brain. Human cells (macrophages, yellow color) are majorly observed
at meninges and perivascular spaces in humanized mouse brain. Mouse cells (resting glia
and neurons) are showed in green colors. (c) HIV-1 infected humanized mouse brain.
Infected human macrophages carry HIV-1 (green) into the brain and release proinflammatory cytokines, chemokines viral proteins, that leads to activated glia (red)
followed by neuronal excitation (blue) and injury (gray). (d) HIV-1 induced
neuropathology, Mn2+ accumulation and associated MEMRI signal enhancement. Mn2+
(blue and pink circle) enters brain through choroid plexus. Being Ca2+ analog, it enters
neurons through voltage gated Ca2+ channels. Mn2+ is transported anterogradely by
microtubule assembly. Once Mn2+ is released, it is taken up by post-synaptic neurons.
Mn2+ accumulation increases in activated neurons during inflammation resulting in
MEMRI signal enhancement increase (stronger purple outer glow compared to control).
Whereas, Mn2+ uptake and transportation are reduced in injured neurons and thus
MEMRI signal is suppressed
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3.4. Discussion
Humanized mouse model (NSG/CD34+) of HIV/AIDS can, in part, mirror human HIV-1
associated neuropathology [8,9,13] and was used successfully to test ART efficacy [25].
Peripheral VL and human CD4+ T-cell decline are hallmarks of HIV-1 infection in
humans which are reflected in these humanized mice. Moreover, a metabolic
encephalopathy caused by viral infection resulting in micro- and astro- gliosis, myelin
pallor, excitotoxicity and neuronal injury is also seen in both humans and infected mice
[8,9,13,22]. Such spectrums of pathologies make the humanized mice a relevant model for

study. In the present study, altered MEMRI brain signal is seen in HIV-1 infected mice
that serve to assess the complexities of neuropathology that underlie HAND’s clinical
manifestations. Although, MEMRI was used previously to study a range of
neurodegenerative disease models [26-29], this is the first report of its use to study effect
of HIV-1 on humanized mice brain function and anatomy with improved analytical
method.
MEMRI enhancement for HIV-1 infection is linked to reactive astrocytes and
activated neurons. The cellular basis of the enhancement change was investigated in a
previous study and interpreted as elevated neuronal Mn2+ uptake and accumulation
stimulated by astrocyte activation [24]. The associations between MEMRI signal with
reactive astrocytes and neuronal responses was previously observed [24,29,30]. We
previously showed that activated glia do not accumulate excessive Mn2+ but stimulate
neuronal Mn2+ uptake [24]. Thus, MEMRI can be used to monitor virus-associated
neuronal excitotoxicity that occurs as a consequence of neuroinflammation. In the CA3
region, both inflammation and neuronal injury (synaptic and axonal injury) were

98

operative in the infected animals. This is consistent with the fact that neuronal damage
caused by HIV-1 infection begins with synaptic damage, compromised dendrite arbor,
then neuronal death occurs as a consequence of persistent infection and immune
deterioration [31]. Interestingly, in CA3 region, we did not observe MEMRI signal
increase as in CA1 and DG. Indeed, damaged neurons likely influence reduction in
neuronal Mn2+ accumulation. The voxel size of MEMRI was 100 µm3, which contains a
large number of cells. The MEMRI enhancement of each voxel resulted from the
combining effects of activated and injured neurons. Simply, the MEMRI signal
enhancement induced by activated neurons was likely offset by signal decrease in injured
cells. Increasing spatial resolution can partially solve the problem as excited and injured
neurons

may

be

differentiated.

Additionally,

performing

MEMRI

and

immunohistological analysis at multiple time points after the infection may also establish
accurate associations between signal enhancements and neuronal injury.
The cellular mechanisms underlying MEMRI enhancement is summarized in
Figure 3.6. Humanized mice permanently carry human blood cells, and these populate
brain primarily at meninges and perivascular spaces. After HIV-1 infection, infected
human monocyte-macrophages carry HIV-1 into the brain and release pro-inflammatory
cytokines, chemokines, viral proteins. This leads to activation of murine glia followed by
neuronal excitotoxicity and injury, which in turn reflects the brain injuries seen as a
consequence of chronic HIV-1 infection. Systemically administrated Mn2+ enters the
brain through choroid plexus. As a Ca2+ analog, it enters neurons through voltage gated
Ca2+ channels and is transported anterogradely by microtubule assembly. Once Mn2+ is
released, it is taken up by post-synaptic neurons. Reactive astrocytes that arise as a
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consequence of HIV-1 induced neuroinflammation first cause elevated neuronal Mn2+
uptake resulting in increased MEMRI signal enhancement. Neuroinflammation then
results in neuronal injury with consequently suppressed MEMRI signal.
In our parallel works, behavioral tests were used to show memory loss and
cognitive dysfunction in these infected mice [13]. As the hippocampus plays an important
role in memory and cognition, the glial activation and neuronal injury in this brain region
detected in this study may contribute to such behavioral abnormalities. Aside from the
hippocampus, the brain regions that show MEMRI signal enhancement following HIV-1
infection include sub-regions of the olfactory system, sub-cortical, brain stem and
cerebellar regions. These findings suggest that infected mice can suffer motor and
autonomic nervous system dysfunction because of cerebellar and brain stem damage. As
different parts of the brain have variable vulnerabilities to HIV-1 infection [32,33], the
current study provides a unique opportunity for unbiased mapping of region specific
neuropathology.
The MEMRI results are supported by the DTI measures in our parallel study [13].
This study showed altered DTI parameters on hippocampal regions in HIV infected
humanized mice, and association between the DTI parameters and quantitative histology.
In infected human and nonhuman primates, abnormal DTI was found in the frontal and
parietal white matter, putamen, and corpus callosum indicating neuroinflammation and
axonal/myelin injury [34,35]. In parallel, inflammation metabolic abnormalities were
detected by MRS in the basal ganglia, cerebrum, caudate, thalamus, and hippocampus
[34-36]. We acknowledge that a direct comparison of the brain imaging findings in

humans and nonhuman primates with mice is difficult due to differences in anatomy,
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physiology, and neurochemistry. Our results are consistent with these human and nonhuman primate studies.
It is likely that abnormalities seen in these animals were not primarily a result of
active viral replication in nervous system, but largely a consequence of replication in
blood and peripheral lymphoid organs. Until now, studies have shown that peripheral
blood nadir CD4+ T-cells count and viral DNA are systemic predictors of HIV-1 induced
neurocognitive disorders [3,37,38]. However, we did see a trend towards correlation
between MEMRI signal enhancement alteration and a plasma viral load measure, which
is the difference between the maximum value and at 16 WPI. A parallel study found that
viral levels correlated with cortical lactate [13]. The same study also found the correlation
or the trend of correlation between cortical and dentate gyrus DTI parameters and viral
load. Their study along with ours suggested that peripheral viral load might be associated
with the neuropathology reflected by imaging in HIV-1 infected humanized mice. Such a
sensitivity of the brain to peripheral events in these animals indicates a dynamic
pathogenic process; where HIV-1 infected blood cells enter into the brain and cause
disease [39].
We now demonstrate that MEMRI is a sensitive biomarker of HIV-1-induced
neuropathology. However, when inflammation and neuronal impairment occur
simultaneously, both increase and decrease in MEMRI signal can be observed. In order to
improve the specificity of imaging on neuropathology, it is reasonable to combine
MEMRI with other imaging modalities. For example, another study showed that the
cerebral cortex is a primary region of damage in infected mice as demonstrated by MRS
and DTI [13]. Combining MEMRI with MRS and DTI can positively determine
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neuroinflammation (increased MEMRI enhancement and increase in myoinositol), and
may help to detect neuronal impairment (reduced MEMRI enhancement, loss of Nacetylaspartate and creatine, reduced diffusivity, and fractional anisotropy). This package
of imaging modalities will greatly enhance our ability for non-invasive assessment of
HIV-1 induced neuropathology. In addition to assessment of neuronal Mn2+ uptake,
MEMRI can provide precise anatomical details. To this end, we applied a MEMRI-based
NSG mouse brain atlas to assess brain morphology to reveal abnormalities associated
with HIV-1 infection in an animal study. As we expected, we did not find changes in total
brain and sub-structural volumes with altered MEMRI enhancement. This suggests that
neuronal death is limited in infected animals. MEMRI successfully provided both insights
into neuronal function and the measurements of brain anatomy.
The toxicity of Mn2+ was minimized by a carefully designed MnCl2
administration. We have used a fractionated administration scheme first proposed by [40].
In this scheme, MnCl2 solution was injected daily through i.p. with a small dose for
certain days (usually 4-8 days), 4 days for our study. Mice were observed daily after the
injection and we did not observe any Mn2+ induced toxic clinical signs and symptoms. In
toto, we demonstrate that MEMRI can be developed as a biomarker of virus-associated
neuropathology. With a thorough understanding of the relationships between MEMRI
and neuropathology, monitoring the efficacy of brain therapeutics can be realized for
prevention or reversal of virus-associated brain disease.
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CHAPTER - 4
Generation of a Manganese-Enhanced Magnetic Resonance
Imaging (MEMRI)-based NOD/scid-IL-2Rγcnull Mouse Brain
Atlas
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4.1. Introduction
Advancements in genetic engineering enabled wide spread use of transgenic mice for
biomedical research. These mice are extensively used in studies of cell, tissue and
organism growth, differentiation and disease. Immune deficiency induced by affecting
the integrity of the adaptive immune system in NOD/scid-IL-2Rγcnull (NSG) mice
permitted the efficient and sustained engraftment of human immunocytes in mice [1,2].
As a result, these mice are used for studies of a broad range of human diseases covering
the disciplines of oncology, hematology, infectious disease and regenerative medicine. In
particular, our laboratories and others have pursued investigation of human
immunodeficiency virus type one (HIV-1) pathobiology including the studies of viral
reservoirs and direct tissue injuries including the lung and the central nervous system
(CNS) [3-5].
Apropos to studies of end organ diseases associated with HIV-1 infection,
magnetic resonance imaging (MRI) has provided critical insights into the mechanisms of
virus-induced damage as well as repair following antiretroviral therapy (ART). We posit
that such investigations can be substantively improved if specific mouse atlases are
generated. Such an atlas could permit broad longitudinal investigation of brain
morphology under conditions that mimic aspects of human neurologic disease.
Specifically, brain parcellation can automate analyses of structure-wise MRI based
metrics (e.g., T1 and T2 relaxation times, diffusion tensor imaging (DTI) measures,
metabolites concentrations, pharmacokinetics and pharmacodynamics (PK and PD), and
Reproduced with permission from Sajja BR, Bade AN, Zhou B, Uberti MG, Gorantla S, Gendelman HE,
Boska MD, Liu Y; Generation and Disease Model Relevance of a Manganese Enhanced Magnetic
Resonance Imaging-Based NOD/scid-IL-2Rγcnull Mouse Brain Atlas; J Neuroimmune Pharmacol. 2015,
Nov 10; Copyright Springer
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drug biodistribution of magnetically labeled cells and nanomaterials). These works would
serve to complement and extend analyses of morphological aberrations seen during
progressive infection. Such measures could also be harnessed as biomarkers of disease as
well as to determine drug efficacy.
Mouse brain atlases were developed by others [6-13]. Such works were heralded
through the need to integrate gene expression with neuroanatomical data and now
available as an online public resource [14]. Indeed, recent studies have focused on
generating developmental and functional brain atlases [11]. The realization of multidimensional (multi-modality and/or multi-parametric) data is notable [10,15].
Acquisition of high resolution data with high signal-to-noise ratios (SNR)
involves long MRI scanning times that are difficult in a live mouse. To overcome such
difficulties, most researchers have performed ex vivo imaging on brain-in-skull or fixed
brains and created mouse brain atlases. However, tissue deformations that are common
and are linked to the type and duration of brain preparation and fixation methods may
affect the atlases generated. Thus, in vivo MRI data based atlases can help improving
accuracy of brain atlases constructed and can be used for longitudinal analyses of
individual mice. In vivo atlases on C57BL/6J mouse brain were generated before by
others [16,17]. We wished to take this idea a step further in sensitivity through the use of
manganese enhanced MRI (MEMRI). Administration of MnCl2 shortens T1 relaxation
times in most brain structures, improving signal to noise per unit time and providing
excellent contrast between many brain substructures including hippocampus, olfactory
bulbs, cerebellum, and cerebral cortical layers as noticed in the present study and
previous studies [18,19]. This allows T1-weighted brain MRI at high field strength to be
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used to acquire high resolution in vivo images while providing enhanced contrast for
brain structure identifications. As high-resolution 3D MRI show significant
neuroanatomical differences between mouse strains [20], generation of a brain atlas on
the same genetic background as used for a disease model serves to enhance accuracy of
brain tissue segmentation on MRI. To these ends, the current study developed a 3D in
vivo MEMRI atlas of NSG mouse.

4.2. Materials and methods
4.2.1. Experimental animals
Nineteen NSG mice (male, weight = 28.5 ± 2.4 grams, age ~ 1 year) from a University of
Nebraska Medical Center (UNMC) breeding colony were used in study. Animals were
maintained in sterile microisolator cages under pathogen-free conditions in accordance
with ethical for care of laboratory animals at UNMC set forth by the National Institutes
of Health. All procedures were approved by the University’s Institutional Animal Care
and Use Committee. Seven human CD34+ hematopoietic stem cells (HSC) reconstituted
(humanized) NSG mice (male, weight = 22.1 ± 5.3 grams, age ~ 1 year) were scanned
using MEMRI to study brain morphology. Additional 6 NSG mice (male, weight = 30.6
± 2.9 grams, age ~ 1.5 years) were included in the study for whole brain T2-weighted
MRI data acquisition without MnCl2 administration.

4.2.2. Human CD34+ HSC reconstitution (humanization) of NSG mice
CD34-NSG mice were generated as described in [5]. Human CD34+ HSC were obtained
from cord blood (Department of Gynecology and Obstetrics, UNMC) and enriched to
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high purity by magnetic bead selection (Miltenyi Biotech Inc., Auburn, CA). The purity
of CD34+ cells was >90% by flow cytometry. Cells were transplanted into newborn mice
irradiated at 1Gy using a C9 cobalt 60 source (Picker Corporation). CD34+ cells were
injected intrahepatically at 105 cells/mouse in 20 µl of PBS using a 30 gauge needle. The
levels of engraftment and number of human cells in peripheral blood were analyzed by
flow cytometry (Dash et al., 2011).

4.2.3. MnCl2 administration
MnCl2.4H2O (Sigma-Aldrich, St Louis, MO) was added to saline (0.9% w/v of NaCl
solution) to make 120 mM MnCl2 solution. MnCl2 was administered at a dose of 125
mg/kg bodyweight using intravenous (i.v.) injections through the tail vein. MnCl2 was
injected using a syringe pump (Harvard Apparatus, MA) at the rate of 125 µL/hour. The
dosing scheme was designed based on our experience in MEMRI and several previous
studies [19,21-24]. Mice were placed on an electrically heated tail vein injection platform
(Braintree Scientific, MA), and were anesthetized by inhalation of isoflurane in 100%
oxygen. Breathing rate, cardiac rate and blood oxygen saturation were continuously
monitored. Anesthesia level was varied from 0.3% to 1.5% isoflurane to maintain the
breathing rate between 40-100 breaths per minute. Immediately after the injection, the
mouse was placed on a heating pad in the cage, and its behavior was observed up to four
hours to detect the side effects of MnCl2. The animal was then returned to the animal
facility and scanned 24 hours later.

4.2.4. MRI data acquisition
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MRI of the 19 NSG mice used for atlas generation were scanned 24 hours after MnCl2
administration on Bruker Biospec 70/20 (Bruker, Billerica, MA) operating Paravision 4.0
with a custom-built 18 mm birdcage volume coil. The humanized mice that were used to
study the effect of humanization on brain volume were scanned using the same MRI
scanner operating Paravision 5.1. An 82 mm actively decoupled volume resonator was
used for signal transmission and a four-channel phase array coil was used for reception.
Mice were anesthetized by inhalation of isoflurane in 100% oxygen and
maintained 40-80 breaths/minute. Three-dimensional T1-weighted data were acquired
using a Rapid Acquisition with Relaxation Enhancement (RARE) sequence with the
following parameters: Repetition time (TR) = 400 ms, Effective echo time (TE eff) = 7.2
ms, RARE factor = 4, number of averages = 1, image matrix = 176 × 128 × 128 with 100
µm isotropic pixel size, total scan time = 27 min, anterior-posterior as the readout
direction. MRI data were acquired from both normal and humanized mice. Threedimensional T2-weighted MRI were obtained from six NSG mice without MnCl2
administration using the same scanning parameters as for 3D T1-weighted data except:
TR/TEeff = 1500/36 ms, RARE factor = 8, number of averages = 1, total scan time = 1h
55m.

4.2.5. Population averaged MRI mouse brain
All MR brain images were manually brain extracted by separating brain from extracranial
tissue using Analyze 10.0v software (www.analyzedirect.com). All brains were registered
to median size brain in the group using rigid image registration. Population average brain
was created by averaging all registered individual brain images. Then all individual brain
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images were iteratively (3 times) affine registered to population average brain and
average was updated at each iteration [6]. Finally, nonlinear registration of individual
brain images to the average was performed using Large Deformation Diffeomorphic
Metric Mapping (LDDMM) to align differences. To minimize the interpolation errors,
transformation matrices from individual registrations were combined and applied in one
step to each original MRI to generate the final average. All the registration procedures
were performed using Diffeomap 1.6v as implemented in DTIStudio software
(www.mristudio.org). The final step was to sharpen the boundaries between anatomic
features (enhanced brain) by applying the Laplacian as:
𝑔(𝑥, 𝑦) = 𝑓(𝑥, 𝑦) − ∇2 𝑓(𝑥, 𝑦)
where g(x, y) and f(x, y) represent enhanced and input images respectively, and 2
represents the Laplacian operator.

4.2.6. Structures delineation and labeling
Paxinos atlas (Paxinos and Franklin, 2001) and Allen brain digital atlas [14]
(http://mouse.brain-map.org/) were followed as reference for identifying and naming
different structures on the averaged MEMRI brain images. Amira 5.21v VSG software
(www.amira.com) was used for generating colored labels of brain structures. A three
dimensional view with connected cursor was used for accurate identification of various
structures.

4.3. Results
4.3.1. Brain structures labeling
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Representative slices from three orthogonal cross-sections of the population averaged
MRI are shown in the first column of Fig. 4.1. The second displays the same slices with
Laplacian edge enhancement. Improved contrast between structures is realized. The third
column shows the manually labeled structures using Amira software. Significant image
contrast seen is due to MnCl2 and allowed the identification and delineation of 41 brain
structures from the cerebrum (CH), brain stem (BS), cerebellum (CB), fiber tracts (FB),
and ventricular systems (VS). All the identified structures’ names are listed in Table 4.1.
To the best of our knowledge this is the highest number of structures identified on in vivo
mouse brain MRI.
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Figure 4.1. Columns: First: Three orthogonal planes of population average MRI. Second:
Edge enhancement of images in first column. Third: Identified structures on these planes:
AMY,

ac,

CBXgr,
(po+sg),
VL,
PAG,

AON,

CBXmo,
DN,

EPI,

CA1_CA2_SUB,
CBwm,
RFB,

MY,

AOB,

MOBgl,

P,

PRT,

RMB,

AQ,
FN,

cc,
GP,

MOBgr,
SN,

CA3,

Central AMYN,

Isocortex,
HY,
PIR,

TH,

CP,

IC,
opt,

V3,

DG-mo,
IP,

LSX,

PALc,
V4,

DG-

MS,

STRv (Note:

Structures ac, AQ, DN, RFB, FN, IP, V3, and V4 are not presented in the third column
of the figure)
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Table 4.1. List of brain regions labeled on MEMRI brain atlas.

Region

Structure

CH: Cerebrum
Isocortex: Isocortex

Isocortex: Isocortex

MOBgl: Main olfactory bulb, glomerular layer
MOBgr: Main olfactory bulb, granule layer
OLF: Olfactory
areas

AOB: Accessory olfactory bulb
AON: Anterior olfactory nucleus
PIR: Piriform area

CA1_CA2_SUB: Field CA1 + Field CA2 + Subiculum
CA3: field CA3 of hippocampus
HPF: Hippocampal
formation

DG-mo: Dentate gyrus_molecular layer
DG-(po+sg): Dentate gyrus_(polymorph layer + granular
layer)

CP: Caudoputamen
STR: Striatum

STRv: Striatum ventral region
LSX: Lateral septal complex

PALc: Pallidium, caudal region
PAL: Pallidum

GP: Globus pallidus
MS: Medial septal nucleus
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AMY: Amygdala

AMY: Amygdala

FB: Fiber tracts
cc: corpus callosum
opt: optic tract
ac: anterior commissure
RFB: Rest of fiber tracts
BS: Brain stem
TH: Thalamus
EPI: Epithalamus
HY: Hypothalamus
IC: Inferior colliculus
PAG: Periaqueductal gray
PRT: Pretectal region
SN: Substantia nigra
RMB: Rest of midbrain
P: Pons
MY: Medulla
CB: Cerebellum
CBXmo: Cerebellar cortex, molecular layer
CBXgr: Cerebellar cortex, granular layer
CBwm: Cerebellar white matter
FN: Fastigial nucleus
IP: Interpose nucleus
DN: Dentate nucleus
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VS: Ventricular system
VL: Lateral ventricles
V3: Third ventricle
AQ: Cerebral aqueduct
V4: Fourth ventricle
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4.4. Discussion
We have developed a 3D in vivo MEMRI brain atlas for NSG mice containing 41 sub
regions. We acknowledge that although this is not the first mouse brain atlas made, it is
the sole one constructed by MEMRI for NSG mice analyses. Majority of previous such
constructions were made on fixed or post-mortem in situ brains [7,9,10]. However, such
prior works may not provide accurate assessment of in vivo volumetric and geometrical
changes amongst brain regions [16,25]. Indeed, fixation protocols cause alterations in
analyses for brain morphology even when MRI data with high resolution and SNR are
employed. To this end, the present in vivo MEMRI brain atlas allows longitudinal
quantitative morphological studies.
There are some advantages of the present approach. First, due to MnCl2 ability to
selectively reduce local T1 relaxation times, the MEMRI provided increased contrast to
noise ratio. Second, boundaries between brain structures are enhanced by Laplace
Transform image processing. Third, specific molecular and granular layers in the brain
regions such as the olfactory bulb and cerebellum were identified (Fig. 4.1.). Through
such an approach, 41 structures on averaged in vivo MRI were delineated and then
labeled. This is a significant improvement from prior 3D in vivo MRI atlases that enabled
only half of the MEMRI-identified brain structures to be processed [16,17]. The
developed atlas is made available to researchers through Neuroimaging Informatics Tools
and

Resources

Clearinghouse

(https://www.nitrc.org/projects/memribrainatlas/).

4.5. Conclusion

(NITRC)

website
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An in vivo MEMRI-based atlas was generated for brains of NSG mice. Forty-one brain
structures were identified to provide a coordinate system for spatial normalization. The
atlas provides a database for studies of brain morphology, metabolomics, MR metrics,
disease pathobiology, and drug pharmacokinetics in a range of infectious, inflammatory
and degenerative disease of the nervous system.
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CHAPTER - 5
Potential of N-acetylated-para-aminosalicylic Acid to
Accelerate Manganese Enhancement Decline for Long-term
MEMRI in Rodent Brain
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5.1. Introduction
Manganese (Mn2+)-enhanced MRI (MEMRI) is a powerful imaging tool to measure
rodent neural structure, function and linked pathways [1-3]. It is facilitated by Mn2+ entry
into neurons that occurs through calcium (Ca2+) channels. Here, Mn2+ ions accumulate in
neurons and are transported along axons. Such ion trafficking reflects neuronal function
and networks [1-5]. Mn2+ is an excellent T1 shortening paramagnetic contrast agent
inducing signal enhancement on T1-weighted (T1-wt) MRI. The retention of Mn2+ in
brain is prolonged with a half-life (t1/2) of 51 to 74 days [5]. Such ion retention allows
studies of brain function performed on non-restrained awake rodents [6-10]. In this
context, Mn2+ administration, sensory stimulation and/or behavioral tests are performed
outside the MRI scanner and prior to imaging tests. Studies have shown that brain
activities that took place days before imaging tests could be detected using appropriate
Mn2+ administration schemes such as implanted osmotic pump infusion [9,10]. The long
Mn2+ brain retention time also enables the monitoring of Mn2+ axonal transportation for
studies evaluating neural pathways[11-13]. MEMRI is also proven a valuable tool in
neurodegenerative disorder studies using rodents [14-25]. However and despite such
advantages, its application is limited in the longitudinal follow-up of neurodegenerative
disorders due to the prolonged washout time of Mn2+. During the time span of the studies
that can be as long as weeks and even months, repeated Mn2+ administration is usually
necessary to keep brain Mn2+ concentration consistent among imaging sessions. This
requires carefully designed dosing if imaging needs to be performed before the residual
Reproduced with permission from Bade AN, Zhou B, McMillan J, Narayanasamy P, Veerubhotla R,
Gendelman HE, Boska MD, Liu Y; Potential of N-acetylated-para-aminosalicylic acid to accelerate
manganese enhancement decline for long–term MEMRI in rodent brain; J Neurosci Methods. 2015, Aug
15; Copyright Elsevier
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Mn2+ from preceding administrations is eliminated. Infusion using commercially
available osmotic pumps may keep brain Mn2+ concentration consistent for up to six
weeks (Alzet, Cupertino, CA), which is usually not sufficient in time to evaluate the
progression of neurodegenerative disorders in rodents. Moreover, repeated or continuous
Mn2+ administration can cause secondary toxicities [26]. One solution is to accelerate
Mn2+ brain elimination after each MEMRI tests and as such limit the effect of residual
Mn2+ on the MEMRI evaluation. Accelerated Mn2+ washouts may also serve to minimize
Mn2+ toxicity.
With this in mind, we tested whether N-acetylated-para-aminosalicylic acid
(AcPAS) could accelerate Mn2+ elimination from brain. AcPAS, an N-acetylated
metabolite of para-aminosalicylic acid (PAS), was previously used to treat human
manganism, a disorder which parallels several of the clinical features of Parkinson’s
disease [27]. Treatment of Mn2+ intoxication is linked to PAS chelation [28,29].
Chelation is the binding of organic compounds and metal ions. The brain distribution,
metabolism, and time-concentration relationships of PAS and its major metabolite,
AcPAS, were previously investigated [30,31]. The results demonstrated that AcPAS
chelates Mn2+. AcPAS has higher brain concentration and possesses a longer t1/2 than
PAS. Herein we demonstrate that AcPAS can be employed to improve the MEMRI utility
by permitting serial brain measurements in health and disease.

5.2. Materials and Methods
5.2.1. Study Design
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C57BL/6 mice were used in this study. Mice were housed in the University of Nebraska
Medical Center (UNMC) laboratory animal facility according to the American Animal
Association and Laboratory Animal Care guidance. All procedures were approved by the
Institutional Animal Care and Use Committee at UNMC. The kinetics of AcPAS in brain
tissue and plasma was first studied using high-performance liquid chromatography
(HPLC) using one group of mice. Another group of mice was first administrated MnCl2
via the intraperitoneal (i.p.) route, followed with PBS (n =3), low dose (n = 3, 100
mg/kg), medium dose (n = 3, 150 mg/kg) and high dose AcPAS (n = 3, 200 mg/kg) three
times daily for two weeks. The doses and administration scheme were designed based on
the previous PK studies of AcPAS [30,31]. MRI was performed one day after the MnCl2
administration followed by AcPAS/PBS treatment. Two more MRI scans were performed
at one and weeks of AcPAS/PBS treatment. After the last MRI, the mice were
immediately euthanized for inductively coupled plasma mass spectrometry (ICP/MS)
analysis of brain Mn2+ concentrations. The timeline of the study design is shown in Fig.
5.1. Three animals were randomly selected from the above 12 AcPAS/PBS-treated mice
and were scanned before any drug administration for baseline measurements of MRI and
ICP/MS.

5.2.2. AcPAS Synthesis
AcPAS was synthesized by a modified procedure [32]. Briefly, p-aminosalicylic acid
(0.33 mol), was dissolved in 100 ml of 2 M hydrochloric acid and stirred with sodium
acetate (0.33 mol) in water at 0° C. The reaction mixture was stirred overnight with 50 ml
of acetic anhydride at room temperature. The brown precipitate obtained was filtered,
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washed, dried and dissolved in 0.1M sodium hydroxide then stirred overnight. The
resulting solution was adjusted to pH 2 with HCl. The product was extracted with ethyl
acetate (3 × 75 ml) and the extracts were dried over anhydrous sodium sulphate. The
solid residue was washed with hexane to produce 52 % yield of pure AcPAS. The
identity of AcPAS was confirmed by NMR with > 99 % purity.

5.2.3. High performance liquid chromatography (HPLC)
AcPAS (200 mg/kg) was administered to mice (n = 9) by i.p. injection. Plasma was
collected at 0.5, 1, 2, 6 and 12 hours. Mouse peripheral blood samples (100 µl) were
collected from submandibular vein (cheek bleed) by using sterile lancets (MEDIpoint,
Inc., Mineola, NY) in EDTA coated tubes. Plasma was separated by centrifugation of
blood samples at 1,800 rpm for 8 min at 4°C within 1 h of sample collection and stored at
-80°C until analysis. Brain tissues (cortex, thalamus, olfactory bulb) of same group of
mice administered with the same dose of AcPAS were collected at 6, 8 and 12 (n = 3 for
each time point) hours after administration. AcPAS from plasma and tissues were
extracted using acetonitrile. AcPAS was quantified by HPLC according to the method of
Sugamori et al. [33]. Briefly, extracted plasma or brain samples were injected in duplicate
(20µl) onto a Shimadzu HPLC (Shimadzu Scientific Instruments, Columbia, MD)
containing a Synergi 4µ Hydro-RP column (4.6 × 150 mm) (Phenomenex, Torrance, CA)
and extruded using an isocratic mobile phase of 7% acetonitrile/1% acetic acid/0.1%
triethylamine at a flow rate of 1.6 ml/min. AcPAS were detected at a wavelength of 270
nm and quantitated by peak comparisons to a standard curve (0.05-50 µg/ml).
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5.2.4. MnCl2 and AcPAS treatment
MnCl2·4H2O (Sigma-Aldrich, St Louis, MO) was added to 0.9% w/v NaCl2 (Hospira,
Lake forest, IL) to make 50 mM MnCl2 solution. MnCl2 solution was delivered i.p. at a
dose of 60 mg/kg consecutively four times at 24 hour intervals. The fractional
administration scheme was designed to minimize Mn2+ toxicity [34]. After injection, the
mice were observed daily to monitor potential Mn2+ toxicities. AcPAS injection started
one day after the MnCl2 administration. AcPAS (1 mg) was mixed with 1 μl DMSO in a
glass container. More (1 – 2 μl) DMSO was added until the compound was dissolved.
Physiological saline (0.9% NaCl) was added to dilute the solution to 20 mg/ml AcPAS.
The solution became a suspension with addition of saline. It was then stored at 4 oC.
Before each injection, the suspension was thoroughly mixed by shaking. AcPAS was
injected i.p. 3 times per day at eight-hour intervals for two weeks. Before each drug
injection, the animal was observed for any abnormal changes in behavior, hair coat, facial
expression, ambulation and body weight.

5.2.5. MRI
MRI was performed on a Bruker Bioscan 7 Tesla/21 cm MRI (Bruker, Billerica, MA)
operating Paravision 5.1 with a 82 mm quadrature volume resonator and a 4-channel
phased array receive coil. Mice were anesthetized by inhalation of isoflurane in 100%
oxygen and maintained 40-80 breaths/minute. Mice were scanned using T1 mapping (fast
spin echo with variable TR from 0.4 s to 10 s, TE = 7.0 ms, 12 coronal slices, slice
thickness = 0.5 mm, in-plane resolution = 0.156 × 0.156 mm2, FOV = 20 x 20 mm2) and
three-dimensional T1W MRI (gradient recalled echo, TR/TE = 20/4.5 ms, flip angle =
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20o, FOV = 19.2 (Left - Right) x 19.2 (Superior - Inferior) x 30.0 (Anterior - Posterior)
mm3, spatial resolution = 0.1 × 0.1 × 0.1 mm3).
To reduce the influence of the inhomogeneous signal reception on the T1W
images by the phased array surface coil, N3 field inhomogeneity correction [35] was first
performed on each image using MIPAV (CIT, NIH). The brain volumes in the T 1W
images were extracted using an in-house Matlab program [36] based on the level sets
method. The brain images were then registered to the MRI-based mouse brain atlas
downloaded from the Laboratory of Neuro Imaging (LONI) at the University of Southern
California using affine transformation first, and then nonlinear transformation
(DiffeoMap, John Hopkins University, Baltimore, MD).
To use signal changes in high resolution T1W MRI to represent Mn2+
accumulation, signal differences need to be scaled to absolute changes in T1 values. This
is achieved by calibrating the baseline and post Mn2+ injection T1W images using T1
values. The T1 maps were first generated using an in-house Interactive Data Language
(IDL) version 8.2 (Exelis Visual Information Solutions, Boulder, Colorado) program
from the data acquired by T1 mapping sequence. Regions of interest (ROI) were then
placed on relatively uniform tissue regions including frontal cortex and caudate on T1
maps and T1W images. The baseline and post Mn2+ injection longitudinal relaxivity and
T1W signal intensity in the ROIs were measured. We assumed that the effect of the
system variation is a constant C (calibration factor) and set system parameter of the postmanganese session as 1, then the measured baseline signal (designated as SblC) is SblC =
CSbl, where Sbl is the true (calibrated) baseline signal. The calibration factor was
calculated as C = (SblC/SMn) × (R1Mn/R1bl), where R1bl and R1Mn are baseline and post Mn2+
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injection longitudinal relaxivities, respectively; SMn is post Mn2+ T1W signal intensity.
The calibration factor was then applied to the baseline T1W image to calculate the true
baseline image: Sbl = SblC / C.
The Mn2+ induced T1W signal enhancement was calculated by: (SMn – Sbl) / Sbl.
This equation was derived by ignoring the T2* effect in the MRI signal generated using a
spoiled gradient recalled echo, and replacing the exponential of (-TR/T1) with the first
two terms of its Taylor expansion. These operations were appropriate as a previous study
has shown that Mn2+ induced T2 change is small compared to T1 reduction [37], and (TR/T1) is small (TR = 20 ms and T1 > 800 ms in most brain regions). Using the LONI
brain atlas, enhancement on brain regions/sub-regions was calculated. A region-by-region
comparison was performed between AcPAS treated groups and PBS controls using
Student’s t-test at each time point.

5.2.6. ICP/MS Analyses
Known weights of thawed brain regions (cortex, thalamus, olfactory bulb), collected from
the animals were decomposed by wet-ashing in vials with six volumes of concentrated
nitric acid followed by microwave (MARS, CEM Corp., Matthews, NC) heating at 200
°C. Total manganese concentrations were determined by ICP-MS (NexION 300Q,
PerkinElmer, MA, USA).

5.2.7. Statistical Analysis
Student’s t-tests were used for all statistical analyses. The significance level was 0.05.
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5.3. Results
5.3.1. AcPAS plasma and brain levels
AcPAS plasma and brain concentrations are shown in Figure 5.2. AcPAS was reduced in
concentration at 2 hours from > 400 to < 23 ng/ml in plasma. The reduction reached eight
ng/ml at 12 hours. AcPAS increased in the cortex, thalamus and olfactory bulbs with time
after six hours. The highest AcPAS tissue concentration was in olfactory bulbs with less
drug in the thalamus and cortex (Fig. 5.2).

5.3.2. MRI
Mn2+ induced enhancement on T1W MRI was seen after 24 hours of MnCl2 injection (Fig
5.3.A-a). Mn2+ induced signal enhancement on T1W MR images was seen in the
hippocampus, cerebellum and olfactory bulbs (Fig 5.3.A-a) [3,4]. The MR images one
week after MnCl2 injection are illustrated in Fig 5.3.A-b with the top panel the PBS and
bottom high dose AcPAS treated mice. The signal intensity was decreased at 1 week in
both groups. Compared to PBS controls, decreased signal intensities were seen in AcPAS
treated mice. This was most notable in the hippocampus and cortex. After 2 weeks of
treatment, AcPAS treated mice (Fig 5.3.A-c, top panel) showed greater decreased signal
intensity than PBS controls (Fig 5.3.A-c, bottom panel) throughout the multiple brain
regions.

5.3.3. Mn2+ enhancement
The enhancement maps are shown in Fig 5.3.B, and quantified region-specific
enhancement results are listed in Table 1. After 24 hours, Mn2+ induced enhancement is
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throughout the whole brain (96% enhancement) with the relatively high enhancement on
olfactory system (Olf, 97%), lateral olfactory tract (lo, 136%), optic chiasm (ox, 98%),
hippocampus (HIP, 97%), hypothalamus (Hy, 98%), interpeduncular nucleus (IP, 97%),
and cerebellum (Cb, 96%) regions (Fig 5.3.B-a, 1st column in Table 5.1). The brain
region abbreviations follow the conventions in the Paxinos and Franklin mouse brain
atlas. Natural enhancement decline was clearly seen in PBS controls after one week from
85-136% to 30-62% (Fig 5.3.B-b top panel, 2nd column in Table 5.1). Mice treated with
low (100 mg/kg) and medium (150 mg/kg) doses did not show significant difference
compared to PBS controls (data not shown). The enhancement in high dose (200 mg/kg)
AcPAS treated mice was lower than in PBS animals (Fig 5.3.B-b). The enhancement
difference was significant (p < 0.05) on substantia nigra (SN), corpus callosum (cc),
thalamus (Th), hippocampus (HIP) and olfactory bulb (Olf) regions (3rd column in Table
5.1).
The enhancement decreased significantly after two weeks in PBS controls to 2259% (Fig 5.3.B-c top panel, 4th column in Table 5.1). After two-weeks, medium dose
(150 mg/kg) AcPAS treated mice showed significantly decreased enhancement compared
to PBS controls on fornix (f) and optic chiasm (ox) (5th column in Table 5.1). In high
dose (200 mg/kg) AcPAS treated mice, a number of brain regions showed significantly
decreased enhancement including the caudate putamen (CPu), basal ganglia (BG) and
internal capsule (ic) (6th column in Table 5.1). The whole brain enhancement in high dose
(200 mg/kg) AcPAS treated mice was also significantly less than in PBS controls. The
brain regions with significantly reduced enhancement in high dose (200 mg/kg) AcPAS
treated mice are shown in Fig 5.4.

139
Manganese concentrations measured by ICP/MS in mouse brains at 24 hours after
MnCl2 administration were 183±25.8 parts per billion (ppb) in cortex, 280±29.2 ppb in
thalamus, 203±14.8 ppb in hippocampus, and 507±164 ppb in olfactory bulbs. The
concentrations were presented as mean±SEM. The concentrations decreased in PBS
treated controls after 2 weeks to 61.6±1.45, 71.7±2.96, 57.6±7.61 and 170±21.4 ppb in
cortex, thalamus, hippocampus and olfactory bulbs, respectively. The concentrations in
high dose AcPAS treated mice at two weeks were 74.3±9.29, 85.3±22.2, 72.8±26.6, and
119±19.4 ppb in cortex, thalamus, hippocampus and olfactory bulbs, respectively. No
significant difference was found between saline controls and AcPAS treated mice (p >
0.1, data not shown).

5.4. Discussion
This study investigated the abilities of AcPAS treatment to affect repeated MEMRI
measurements of brain structure and function. We demonstrate that, even though AcPAS
did not lead to accelerated Mn2+ brain elimination, it suppressed significantly Mn2+induced MRI enhancement after about two weeks treatment when using the high dose
(200mg/kg × 3 daily). Based on these findings, AcPAS has the potential to enable
repeated MEMRI measurements and minimize Mn2+ toxicity.
AcPAS can be rapidly eliminated from blood within an hour. As soon as six hours
after the injection, AcPAS has entered the brain and its concentration increased over the
next six hours. This finding is in agreement with a previous PK study of PAS and AcPAS
(32). These findings suggested that, to achieve sufficient brain concentrations, AcPAS
must be administrated by multiple injections over a day or by continuous infusion.
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Therefore the dosing and administration scheme were designed based on these findings
and previous PK and PD studies of AcPAS (32). The accelerated Mn2+ washout induced
by AcPAS is different among brain regions. HIP, TH, CPu are among the regions of
fastest washout. This is in the agreement of a previous study showing high AcPAS
concentration in these regions [30].
The ICP/MS data suggested that AcPAS failed to speed the elimination of Mn2+.
However, MRI results showed faster enhancement decline in AcPAS treated mice
compared to PBS controls at high dose. The discordant results can be explained as
follows. The chelation of paramagnetic Mn2+ by AcPAS limits its interaction with water
molecules, and thus causes the decrease in Mn2+ induced signal enhancement. On the
other hand, the high tissue affinity and long t1/2 of AcPAS limit the elimination of
chelated Mn2+ from brain.
The study showed that an average 17% enhancement remains in brain after 2week high dose AcPAS treatment. Further experiments are necessary to determine the
time to complete elimination of enhancement. Nevertheless, AcPAS provides an option
for serial studies with a shorter time interval compared to the inherent Mn2+ washout of
17-26 weeks [5]. We did not observe any side-effects of AcPAS in the animals. It is quite
possible that higher dose (> 200 mg/kg) AcPAS treatments would eliminate the
enhancement more quickly than the highest dose used in this study.
A more comprehensive study is being planned, in which a second MEMRI
experiment will be performed after AcPAS treatment to ensure the enhancement
efficiency still holds, and Mn2+ update and retention by neurons are not affected after the
AcPAS treatment. The study will prove the feasibility of using AcPAS for repeated
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MEMRI. We do not expect AcPAS treatment causes brain water relaxivity changes,
because AcPAS is an organic compound cleared from brain with a half-life of 100-200
minutes [30], and is diamagnetic. To prove the hypothesis, one more group of mice will
be added in the planned study that will receive AcPAS treatment and MRI scans but not
MnCl2 injection. This group is to detect any effect on brain water relaxivity caused by
AcPAS treatment.
PAS [4-amino-2-hydroxybenzoic acid (Paser); CAS number, 65-49-6] has been
well known as an antituberculosis drug since the 1950s [38]. Its side effects on humans
have been investigated [38]. The toxicity of its tissue metabolite - AcPAS needs to be
further studied for use in MEMRI. In this study, no abnormal changes in behavior, hair
coat, facial expression, ambulation and body weight were found in the animals. Even
though AcPAS does not accelerate the removal of Mn2+ from brain, its chelation of Mn2+
is believed to minimize Mn2+ toxicity. If AcPAS is to be used in neurological disease
studies using rodent models, its compatibility with the studies needs to be considered to
assure its administration will not advertently affecting key physiological/disease-related
parameters. In conclusion, we showed that, while AcPAS does not eliminate Mn2+ from
brain, it accelerates Mn2+ induced enhancement decline in MRI. The results suggested the
potential to use AcPAS for serial MEMRI measurements of voltage-gated calcium
channel activity and morphology in rodent brains. In future studies, we will follow the
animals longer to study the long-term effects of AcPAS on Mn2+ elimination and parallel
MEMRI test results.
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MnCl2 i.p. injection

AcPAS/PBS i.p.
injection
Euthanasia
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Figure 5.1. Study design. Mice were first administrated with MnCl2, followed with PBS
(n =3), low dose (n = 3, 100 mg/kg), medium dose (n = 3, 150 mg/kg) or high dose
AcPAS (n = 3, 200 mg/kg) for two weeks. MRI was performed on the mice at one and
two weeks after MnCl2 administration. After the second MRI, the mice were immediately
euthanized for ICP/MS analysis of brain Mn2+ concentrations.
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Figure 5.2. AcPAS concentrations measured by HPLC in plasma (blue line) and in the
brain regions (red lines). The concentrations in plasma were measured in ng/ml (left
vertical axis), and in brain were measured in ng/mg (right vertical axis). The error bar at
each time point shows the mean standard error of the measurement.
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Figure 5.3. (A) MRI data. (a) Averaged MRI of mice (n = 9) at 24 hours after MnCl2
administration. (b) Averaged MRI of PBS controls (n = 3, top panel) and high dose
AcPAS treated mice (n = 3, bottom panel) at one week after MnCl2 administration. (c)
Averaged MRI of PBS controls (n = 3, top panel) and high dose AcPAS treated mice (n =
3, bottom panel) at two weeks after MnCl2 administration. (B) Manganese enhancement
maps corresponding to Figure 3A.
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Figure 5.4. Brain regions with significantly less enhancement in mice after one (A) and
two (B) weeks high dose AcPAS treatment compared to in PBS controls. The regions are
shown in coronal slices, whose locations are indicated using red lines on the sagittal
slices in the leftmost column.
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Table 5.1. Brain regions with significantly decreased enhancement in mice after 1 and 2
weeks high dose AcPAS treatment compared to in PBS controls.
Enhancement data are presented as percentage and in Mean ± Standard deviation.
*

: p < 0.1; **: p < 0.05
0 week
All (%)
f
Ox
Cb
SN
IP
cc
Hy
Th
CP
u
BG
HIP
lo
Olf
Cx
ic
fr
Br

1 week
High Dose
(%)
27±7
37±7
32±7
30±7**
37±11*
27±6**
37±5
28±5**

2 weeks
Mid Dose
(%)
21±0**
23±3**
21±3
16±4
24±2
17±2*
23±2*
20±1

89±13
98±14
96±13
91±12
97±14
87±12
98±13
89±13

PBS
(%)
35±7
37±11
39±7
40±4
50±3
37±4
41±5
38±4

90±12

40±4

30±8*

29±7

20±1*

17±4**

95±13
97±13
136±24
97±13
95±14
85±16
95±17
96±16

42±4
42±4
62±20
45±8
40±8
30±4
38±6
36±9

33±8*
33±6**
60±11
31±8**
32±6*
24±7
32±4*
29±7

31±8
29±8
59±12
28±5
29±8
22±6
27±10
27±6

21±1
20±0
45±2
22±1
23±0
16±6
23±5
22±2

17±6**
17±5**
39±9**
20±6*
18±4*
13±4**
17±6
17±5**

PBS
(%)
29±2
35±6
28±6
22±8
31±9
25±6
33±7
25±7

High Dose
(%)
18±6**
22±5**
19±4*
12±5*
18±7*
15±4**
17±5**
16±5*
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CHAPTER – 6
Summary, Limitations, and Future Directions
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Translational animal models of brain disorders remain essential for thorough
understanding of the patho-biological mechanisms, as comprehensive research cannot be
done in controlled and reproducible manner on humans. Research directed at
morphological, pathophysiological mechanisms and functional activities of the CNS can
be realized through imaging systems in vivo. A significant literature now demonstrates
the importance and utility of MRI towards unraveling the complex neural system, healthy
or diseased. MRI is a non-invasive and versatile imaging tool. It allows longitudinal,
three-dimentional assessment of tissue anatomy, pathophysiology, function and
metabolism.

Due to these properties MRI has achieved widespread success in

experimental neuroscience studies. Yet, there is a room for improvement in MRI
specificity and sensitivity, and this can be achieved by using contrast agents, especially
Mn2+.
MEMRI opens the great opportunity to study complex paradigms in freely
behaving animals. By taking the advantage of chemical and biological properties of Mn2+
in living organisms, MEMRI has been successfully applied in the studies of several
neurological diseases using animal models, such as stroke, Parkinson’s disease,
Alzheimer’s disease, epilepsy, and other brain disorders to assess detailed information
about neuronal activity, morphology and neuronal tracts as well as rate of axonal
transport. Mn2+ is toxic, however, MEMRI revels new patho-biological information that
might be otherwise difficult to gain. Properly planned administration of Mn2+ and close
monitoring of animals after administration is required to avoid toxicity and pain to
animals. Although previous studies highlight the potential of MEMRI for brain imaging,
the limitations still exist concerning the use of Mn2+ in living animals. The development
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of MEMRI applications in neuroscience research are at the beginning level. Therefore,
development of methods of MEMRI for experimental studies remains essential for
diagnostic findings as well as development of therapeutic strategies.
In the first study (Chapter - 2), we investigated role of glia and neurons in
MEMRI signal enhancement during inflammation. Unlike other contrast agents such as
gadolinium, iron oxide, and iron platinum Mn2+ can provide unique intracellular insights
about brain pathophysiology. Nonetheless, a critical question that remained poorly
understood was the brain cells that serve as sources for the MEMRI signal enhancement
during inflammation. In this study, we investigated MEMRI’s abilities to detect glial
(astrocyte and microglia) and neuronal activation signals following treatment with known
inflammatory inducing agents. The idea was to distinguish between gliosis (glial
activation) and neuronal injury for the MEMRI signal and as such use the agent as a
marker for neural activity in inflammatory and degenerative disease. This work
demonstrated that cytokine-induced glial activation facilitates neuronal uptake of Mn2+ in
vitro. Glial Mn2+ content was not associated with glial activation. After in vitro
conformation, we validated our hypothesis in vivo. MEMRI was performed on mice
injected with lipopolysaccharide by IC route. MEMRI signal enhancement was
associated with increased neuronal activity. In conclusion, results supported the notion
that MEMRI reflects neuronal excitotoxicity and impairment that can occur through a
range of insults that include neuroinflammation and MEMRI signal enhancement in the
CNS is induced by astrocytic activation by stimulating neuronal Mn2+ uptake.
In the second study (Chapter - 3), we evaluated the efficacy of MEMRI in
diagnosing the brain pathology in an animal model of neurodegenerative disease,
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neuroAIDS. Progressive human immunodeficiency viral (HIV) infection commonly leads
to a constellation of cognitive, motor and behavioral impairments. These are collectively
termed HIV-associated neurocognitive disorders (HAND). While antiretroviral therapy
(ART) reduces HAND severity, it does not affect disease prevalence. Despite decades of
research there remain no biomarkers for HAND and all potential co-morbid conditions
must first be excluded for a diagnosis to be made. To this end, we now report that
MEMRI can reflect brain region specific HIV-1-induced neuropathology in chronically
virus-infected NOD/scid-IL-2Rγcnull humanized mice. MEMRI diagnostics mirrors the
abilities of Mn2+ to enter and accumulate in affected neurons during disease. T1 relaxivity
and its weighted signal intensity are proportional to Mn2+ activities in neurons. In 16week virus-infected humanized mice, altered MEMRI signal enhancement was easily
observed in affected brain regions. These included, but were not limited to, the
hippocampus, amygdala, thalamus, globus pallidus, caudoputamen, substantia nigra and
cerebellum. MEMRI signal was coordinated with levels of HIV-1 infection,
neuroinflammation (astro- and micro- gliosis), and neuronal injury. MEMRI accurately
demonstrates the complexities of HIV-1 associated neuropathology in rodents that
reflects, in measure, the clinical manifestations of neuroAIDS as it is seen in a human
host.
In the third study (Chapter – 4), our successful collaboration with Dr. Sajja BR
(Associate Professor, Department of Radiology, UNMC, Omaha, NE) led to generation
of a MEMRI-based NOD/scid-IL-2Rγcnull (NSG) mouse brain atlas. Strain specific mouse
brain MRI atlases provide coordinate space linked anatomical registration. This allows
longitudinal quantitative analyses of neuroanatomical volumes and imaging metrics for
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assessing the role played by aging and disease to the central nervous system. As NSG
mice allow human cell transplantation to study human disease, these animals are used to
assess brain morphology. MEMRI improves contrasts amongst brain components and as
such can greatly help identifying a broad number of structures on MRI. To this end, NSG
adult mouse brains were imaged in vivo on a 7.0 Tesla MR scanner at an isotropic
resolution of 100 µm. A population averaged brain of 19 mice was generated using an
iterative alignment algorithm. MEMRI provided sufficient contrast permitting 41 brain
structures to be manually labeled. The developed atlas is made available to researchers
through Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC) website
(https://www.nitrc.org/projects/memribrainatlas/).
In the fourth study (Chapter – 5), we evaluated the efficacy of N-acetylated-paraaminosalicylic acid (AcPAS) to accelerate Mn2+ elimination from rodent brain. The brain
retention of Mn2+ is relatively long with a half-life (t1/2) of 51 to 74 days causing a slow
decline of MRI signal enhancement following Mn2+ administration. Such slow decline
limits using repeated MEMRI to follow the central nervous system longitudinally in
weeks or months. This is because residual Mn2+ from proceeding administrations can
confound the interpretation of imaging results. To the best of our knowledge, no method
exists to accelerate the decline of the Mn2+ induced MRI enhancement for repeated
MEMRI tests. We investigated whether AcPAS, a chelator of Mn2+, could affect the
decline of Mn2+ induced MRI enhancement in brain thus enabling repeated MEMRI, and
as a consequence broadens the utility of MEMRI tests. Two-week treatment with AcPAS
(200 mg/kg/dose × 3 daily) accelerated the decline of Mn2+ induced enhancement in
MRI. (In the whole brain on average the enhancement declined 83% in AcPAS treated
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mice, while in PBS controls the decline was 73%. We posit that AcPAS could enhance
MEMRI utility for evaluating brain biology in small animals. Further study needed for
detailed understanding.
In general, major disadvantage of MEMRI is the toxicity associated with Mn2+,
which restricted its clinical transformation. As obtained MEMRI contrast is directly
related to accumulation of Mn2+ in excitable cells in activity dependent manner, MEMRI
has been successfully used to study neuronal activation. However, difference in Mn2+
influx and efflux rates (long half-life in brain) or long clearance time allowed to produce
only static activation maps and do not allow to inform about temporal or rapid changes in
neuronal activity (Silva et al. 2012). Also, it remains to be investigated whether MEMRI
detects neuronal deactivation (Silva et al. 2012). We have demonstrated that MEMRI
visualizes reactive astrogliosis (increase in signal intensity) and neuronal loss (decrease
in signal intensity; ongoing study in the lab, data not shown in this thesis). But limitation
is that one of the dominating cellular mechanisms offsets other mechanism to determine
the MEMRI results. MEMRI is still not sensitive enough to detect gliosis and neuronal
loss at the same time. Also, threshold level of cellular activity for generating MEMRI
signal is not studied yet.
In all the studies of this thesis, we have measured and compared T1 signal
intensities on three-dimensional (3D) high-resolution (<= 100 μm pixel size) T1-wt
images for healthy and diseased animals. T1 values were also measured using multi-slice
MRI with lower in-plane resolution. MRI scanner system variation was then estimated
using the T1 values and T1-wt signal. The acquired T1-wt images were then calibrated.
Detailed process of the image calibration is described in chapter - 3 of this thesis. We are
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now developing a fast T1 mapping sequence to directly measure brain T1 values by a 3D
high-resolution fashion. This method will provide more accurate results on brain Mn2+
uptake and accumulation.
There are extensive possibilities for future applications of MEMRI in translational
neuroscience research. The possibility of longitudinal studies enable the measurement of
functional changes in CNS after pharmacological interventions as well as therapeutic
treatment. Integration of MEMRI with multiple imaging modalities will overcome the
limitations of previous single parametric approach and therefore, will establish a
comprehensive study to understand neurobiological mechanisms underlying normal and
abnormal functions.

